---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description. Covers Product description and Place of product in therapy. 303 evidence topics quoted from 172 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Submission planned; BLA planned, with topline pivotal interim data and FDA feedback on the submission pathway expected in the first half of 2027

> “Topline data from the REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway for TSHA-102 expected in the first half of 2027”
> “FDA feedback following CMC Type B meeting expected in the first quarter of 2027”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

> “The interim analysis to support the planned and FDA-aligned BLA submission is expected to occur after all 17 patients complete six months of post-treatment follow-up.”
> “Subsequently, we plan to discuss data from the 6-month interim analysis and next steps toward the BLA submission pathway with the FDA, with topline data and regulatory feedback anticipated in the first half of 2027.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-2.1.1-2"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

##### Development stage: dosing complete in the pivotal and ASPIRE trials

> “All patients in the REVEAL Phase 1/2 (n=12), pivotal (n=17) and ASPIRE (n=4) trials have cleared the acute post-dosing safety monitoring period typically associated with AAV gene therapies with no dose-limiting toxicities observed across all trials.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-2.1.1-4"></a>

##### Designations held for TSHA-102

> “TSHA-102 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the Medicines and Healthcare products Regulatory Agency.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-2.1.1-5"></a>

##### Breakthrough Therapy designation: September 2025

> “In September 2025, the FDA granted Breakthrough Therapy designation to TSHA-102 following the FDA’s review of positive clinical evidence across the 12 patients treated with TSHA-102 in Part A of the REVEAL Phase 1/2 trials.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-2.1.1-6"></a>

##### Regenerative Medicine Advanced Therapy designation: April 2024

> “In April 2024, the FDA granted Regenerative Medicine Advanced Therapy, or RMAT, designation for TSHA-102 in Rett syndrome following the FDA’s review of available safety and efficacy data from the first three patients with Rett syndrome dosed with the low dose of TSHA-102 in Part A of the REVEAL Phase 1/2 Adolescent and Adult trial and the REVEAL Phase 1/2 Pediatric trial.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

> “RMAT designation follows the FDA’s review of available safety and efficacy data from the first three patients with Rett syndrome dosed with the low dose of TSHA-102 (5.7x1014 total vg) across the REVEAL Phase 1/2 adolescent and adult trial and the REVEAL Phase 1/2 pediatric trial.”

Source: [Taysha Gene Therapies RMAT designation announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-regenerative-medicine-advanced)

<a id="topic-2.1.1-7"></a>

##### Fast Track designation: August 2023

> “today announced the U.S. FDA has granted Fast Track Designation (FTD) to TSHA-102, a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.”

Source: [Taysha Gene Therapies Fast Track designation announcement (2023)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-fast-track-designation-granted)

<a id="topic-2.1.1-8"></a>

##### Orphan drug and rare pediatric disease designations: FDA, October 2020

> “today announced that it has received rare pediatric disease designation and orphan drug designation from the U.S. Food and Drug Administration (FDA) for TSHA-102, an AAV9-based gene therapy in development for the treatment of Rett syndrome.”

Source: [Taysha Gene Therapies orphan drug and rare pediatric disease designation announcement (2020)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-receives-rare-pediatric-disease)

| Field | Quoted record |
| --- | --- |
| Generic name | “recombinant serotype 9 adeno-associated virus encoding a codon-optimized human MECP2 gene” |
| Orphan designation | “Treatment for Rett syndrome” |
| Designation date | “10/07/2020” |
| Designation status | “Designated” |

Source: [FDA Orphan Drug Designations and Approvals (2020)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=770520)

<a id="topic-2.1.1-9"></a>

##### Orphan drug designation: European Commission, September 2021

> “today announced that it has been granted orphan drug designation from the European Commission for TSHA-102, an AAV9-based gene replacement therapy in development for Rett syndrome.”

Source: [Taysha Gene Therapies European orphan designation announcement (2021)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-receives-orphan-drug-designation-european-commission-tsha)

<a id="topic-2.1.1-10"></a>

##### Innovative Licensing and Access Pathway designation: MHRA, February 2024

> “In February 2024, we received Innovative Licensing and Access Pathway, or ILAP, designation for TSHA-102 from the U.K. Medicines and Healthcare Products Regulatory Agency.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-2.1.1-11"></a>

##### Rare pediatric disease priority review voucher eligibility

> “The authority for the FDA to award rare pediatric disease PRVs for drugs that have received rare pediatric disease designation currently expires on September 30, 2029.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.1.1-12"></a>

##### FDA interactions: written alignment on the pivotal trial design and the submission pathway

> “On May 28, 2025, we announced that we obtained written alignment from the FDA on key elements of our pivotal Part B REVEAL clinical trial design, following formal discussions enabled by the regenerative medicine advanced therapy, or RMAT, mechanism.”
> “In October 2025, we announced that we finalized alignment with the FDA on the REVEAL pivotal trial protocol and Statistical Analysis Plan, or SAP, that are intended to support the planned BLA submission for TSHA-102, following the resolution of remaining clinical and statistical queries.”
> “Following a Type D meeting with the FDA, we announced on January 6, 2026, that we confirmed prior alignment and obtained further written alignment with the FDA on the ASPIRE trial and the data for inclusion in the planned BLA submission to enable broad labeling of TSHA-102 for patients aged ≥2 years with Rett syndrome.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

> “Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following recent breakthrough therapy Type B meeting”

Source: [Taysha Gene Therapies first quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526207633/d99032dex991.htm)

<a id="topic-2.1.1-13"></a>

##### FDA interactions: chemistry, manufacturing and controls

> “We reached written alignment with the FDA on Chemistry, Manufacturing and Controls, or CMC, requirements to support a planned BLA submission for TSHA-102 following a Type C meeting.”
> “The FDA agreed that this approach may potentially support pooling data from the REVEAL Phase 1/2 trials with data from the ongoing REVEAL pivotal and ASPIRE trials for the planned BLA submission.”
> “We plan to discuss this CMC data with the FDA at a meeting expected to be held in the fourth quarter of 2026 in an effort to further strengthen the CMC package for our planned BLA submission.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-2.1.1-14"></a>

##### Health Canada authorizations

> “In March 2022, our CTA filing for TSHA-102 for the treatment of Rett Syndrome was approved by Health Canada and therefore triggered a regulatory milestone payment of $1.0 million in connection with the Abeona Rett Agreement.”
> “Taysha commenced site activation activities for the REVEAL pivotal trial, following receipt of a No Objection Letter from Health Canada and feedback from the FDA.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Taysha Gene Therapies

> “Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system.”
> “Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-2.1.2.1-2"></a>

###### Nonproprietary name and development code

> “LONIMECGENE RENPARVOVEC [USAN]”
> “lonimecgene renparvovec [INN]”
> “TSHA-102”
> “2856375-48-7”

Source: [FDA UNII NVK87P6NXW](https://precision.fda.gov/uniisearch/srs/unii/NVK87P6NXW)

<a id="topic-2.1.2.1-3"></a>

###### Nonproprietary name: WHO proposed International Nonproprietary Name and substance description

> “lonimecgene renparvovec”
> “gene therapy (Rett syndrome)”

Source: [WHO Proposed INN List 130 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl130.pdf)

<a id="topic-2.1.2.1-4"></a>

###### Brand name

No evidence found.

<a id="topic-2.1.2.1-5"></a>

###### Therapeutic class: self-complementary AAV9 gene transfer therapy

> “TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.”
> “Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-2.1.2.1-6"></a>

###### Licensing: Abeona Rett Agreement

> “In October 2020, we entered into a license agreement, or the Abeona Rett Agreement, with Abeona Therapeutics Inc., or Abeona, pursuant to which we obtained an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses under certain patents, know-how and materials originally developed by the University of North Carolina at Chapel Hill, the University of Edinburgh and Abeona to research, develop, manufacture, have manufactured, use, and commercialize licensed products for gene therapy and the use of related transgenes for Rett syndrome.”
> “We are obligated to pay Abeona up to $26.5 million in regulatory-related milestones and up to $30.0 million in sales-related milestones per licensed product and high single-digit royalties on net sales of licensed products.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.1.2.1-7"></a>

###### Licensing: patent rights in-licensed for TSHA-102

> “We in-license from The Board of Regents of The University of Texas System four pending patent applications worldwide directed to a minigene encoding MECP2 packaged into an AAV vector, and methods of using that vector to treat Rett syndrome.”
> “Under the Abeona Rett Agreement, we also sub-license from the University of Edinburgh and the University of Glasgow 10 pending patent applications worldwide directed to MECP2 expression cassettes for gene therapy.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.1.2.1-8"></a>

###### Rights to the product: Astellas option expired in October 2025

> “In October 2025, the Option Agreement expired without Astellas exercising the GAN Option or Rett Option. Pursuant to the expiration of the Option Agreement, we regained full and unencumbered global rights to TSHA-102.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

> “Following the expiration of the Option Agreement, Taysha now holds unencumbered rights to the TSHA-102 program.”

Source: [Taysha Gene Therapies full rights announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525241415/d35488dex991.htm)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Pharmaceutical form and route of administration

> “Solution for infusion”
> “Intrathecal use”

Source: [EMA paediatric investigation plan decision (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232894-ema-decision-14-april-2025-agreement-paediatric-investigation-plan-granting-deferral-adeno-associated-viral-vector-serotype-9-containing-human-mecp2-gene_en.pdf-0)

<a id="topic-2.1.2.2-2"></a>

###### Dose levels administered in the clinical trials

> “High dose (1x1015 total vector genomes (vg)) and low dose (5.7x1014 total vg) TSHA-102 continue to be generally well tolerated with no severe treatment-related serious adverse events (SAEs) or dose limiting toxicities (DLTs) in all patients treated in the REVEAL Phase 1/2, REVEAL pivotal and ASPIRE trials (N=33) as of the November 2026 data cutoff.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

> “A total of 17 participants aged 6 to <22 years were treated with the high dose (1x10¹⁵ total vector genomes (vg)) of TSHA-102 in this study.”
> “A total of four participants were treated with the high dose (1×10¹⁵ total vg) of TSHA-102, scaled to account for the lower brain volume in 2 to <4 year olds.”

Source: [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### WHO International Nonproprietary Name classification

> “gene therapy (Rett syndrome)”

Source: [WHO Proposed INN List 130 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl130.pdf)

<a id="topic-2.1.2.4-2"></a>

###### FDA substance registry classification

> “LONIMECGENE RENPARVOVEC”
> “INGREDIENT SUBSTANCE”

Source: [FDA UNII NVK87P6NXW](https://precision.fda.gov/uniisearch/srs/unii/NVK87P6NXW)

<a id="topic-2.1.2.4-3"></a>

###### Regulatory classification as a regenerative medicine therapy

> “Gene therapies, including genetically modified cells that lead to a durable modification of cells or tissues may meet the definition of a Regenerative Medicine Therapy.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.1.2.4-4"></a>

###### AHFS classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Investigational status: no approved indication

> “The product is not authorised anywhere in the European Community.”

Source: [EMA paediatric investigation plan decision (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232894-ema-decision-14-april-2025-agreement-paediatric-investigation-plan-granting-deferral-adeno-associated-viral-vector-serotype-9-containing-human-mecp2-gene_en.pdf-0)

> “To date, we have not generated any revenues from the commercial sale of approved drug products, and we do not expect to generate substantial revenue for at least the next few years.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-2.1.2.5-2"></a>

###### Proposed indication: patients aged 2 years and older with Rett syndrome

> “The TSHA-102 clinical development program is designed to support the potential future approval for a broad population of patients aged 2 years and older with Rett syndrome through an efficient and rigorously designed pathway.”
> “In close collaboration with the U.S. Food and Drug Administration, Taysha designed the TSHA-102 pivotal program so that efficacy data from the REVEAL Pivotal Trial in participants aged 6 to <22 years who have reached developmental plateau can be used to represent patients aged 2 to <6 years, while safety data in younger children are generated through the separate ASPIRE Trial to support a broad label for TSHA-102.”

Source: [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/)

> “We also obtained written alignment from the FDA on an extrapolation approach in a separate safety-focused study, which we refer to as the ASPIRE trial, and the data for inclusion in the planned BLA submission to enable potential broad labeling of TSHA-102 for patients aged ≥2 years with Rett syndrome.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-2.1.2.5-3"></a>

###### Population studied: females with a MECP2 loss-of-function mutation

> “We are evaluating TSHA-102 for the treatment of females with Rett syndrome in our REVEAL and ASPIRE clinical trials.”
> “The REVEAL Phase 1/2 Adolescent and Adult Trial, also known as Part A, is a first-in-human, open-label, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of TSHA-102 as a single lumbar intrathecal administration in adolescent and adult females aged 12 years and older with Rett syndrome due to loss-of-function mutation in the methyl-CpG binding protein 2, or MECP2, gene.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Vector construct: self-complementary AAV9 encoding a miniaturized MECP2 with the miRARE element

> “recombinant, self-complementary (dimeric), non-replicating adeno-associated virus serotype 9 (scAAV9) vector encoding a miniaturised form of human methyl-CpG binding protein 2 (MECP2) containing the methyl-CpG-binding domain (MBD) and the NCoR/SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) interaction domain (NID), under the control of a fragment of the mouse MECP2 promoter. The 3' untranslated region is designed to decrease protein expression through RNA interference by containing a microRNA (miR) Responsive Auto-Regulatory Element (miRARE) inserted into the replication dependent histone 1 (RDH1) polyadenylation region. The construct is flanked by adeno-associated virus 2 (AAV2) inverted terminal repeats (ITRs)”

Source: [FDA UNII NVK87P6NXW](https://precision.fda.gov/uniisearch/srs/unii/NVK87P6NXW)

<a id="topic-2.1.2.6.1-2"></a>

###### Intended mechanism: one-time delivery of a functional MECP2 to central nervous system cells

> “TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.”
> “Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS.”
> “TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-2.1.2.6.1-3"></a>

###### Rationale for autoregulation: risks of MeCP2 under-expression and over-expression

> “Because of the risks associated with both under- and over-expression of MeCP2, we have combined high-throughput microRNA, or miRNA, profiling and genome mining to create miRNA-Responsive Auto-Regulatory Element, or miRARE, our novel miRNA target panel.”
> “The miRARE element includes binding sites for endogenous miRNA, which are responsive to MeCP2 levels to prevent overexpression.”
> “By increasing MECP2 levels in MECP2 deficient cells and maintaining healthy levels of MECP2 output of healthy cells, TSHA-102 has demonstrated the ability to produce and maintain safe transgene expression levels in the CNS.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.1.2.6.1-4"></a>

###### miRARE: silencing in cells with normal MeCP2 function and expression in MeCP2-deficient cells

> “TSHA-102 carries a 3’ element, the miR-Responsive Auto-Regulatory Element (miRARE), designed to silence transgene expression in cells with normal MeCP2 function and permit expression in MeCP2-deficient cells”
> “miRARE is designed to SILENCE miniMECP2 transgene expression in healthy, MeCP2+ cells”
> “miRARE is designed to ENABLE miniMECP2 transgene expression in MeCP2-deficient cells”

Source: [Haque et al. (2025)](https://tayshagtx.com/wp-content/uploads/rAAV9-Vector-Biodistribution-in-Brain-and-Spinal-Cord-via-Lumbar-Intrathecal-Infusion-in-Nonhuman-Primates-NHP-Assessing-the-Administration-Route-Leveraged-in-TSHA-102-Rett-Syndrome-Clinical-Trials.pdf)

<a id="topic-2.1.2.6.1-5"></a>

###### Proposed feedback mechanism: microRNA seed sequences in the 3 prime untranslated region

> “miRNA target sites (seeds; red) engineered into the miRARE are proposed to silence transgene expression in response to cellular MeCP2 function.”
> “The miniMECP2 3’UTR carries seeds for at least 10 miRNAs, including 6 in the miRARE.”

Source: [Haque et al. (2023)](https://tayshagtx.com/wp-content/uploads/The-microRNA-responsive-autoregulatory-element-from-TSHA-102-for-Rett-Syndrome-modulates-therapeutic-transgene-expression-in-response-to-cellular-MeCP2-in-mouse-and-human-cell-lines.pdf)

<a id="topic-2.1.2.6.1-6"></a>

###### Self-complementary genome: a transcription-ready transgene

> “In contrast to ssAAV vectors that require conversion of the single-stranded DNA to double-stranded DNA prior to expression, TSHA-102 contains complementary strands of the MECP2 transgene, delivering a transcription-ready transgene to MeCP2-deficient cells for enhanced stability and efficiency”
> “A miRNA-Responsive Auto-Regulatory Element (miRARE) further refines expression by silencing transgene expression in MeCP2-healthy cells while permitting expression in MeCP2-deficient cells”

Source: [Haque et al. (2026b)](https://tayshagtx.com/wp-content/uploads/ASGCT-Superior-expression-of-self-complementary-AAV-and-comparable-functionality-of-mini-and-full-length-MECP2-support-the-design-of-TSHA-102-gene-therapy-for-Rett-syndrome.pdf)

<a id="topic-2.1.2.6.1-7"></a>

###### Transgene: truncated MECP2 retaining the methyl-CpG-binding and NCoR/SMRT interaction domains

> “TSHA-102 is an investigational AAV9 vector containing a truncated, but therapeutically active, version of the human MECP2 gene (miniMECP2), a novel miRNA binding site panel (miRARE), self-complementary AAV2 inverted terminal repeat elements, and a fragment of the endogenous mouse MECP2 promoter that contains both regulatory and putative silencer elements (MeP426)”

Source: [Prasad et al. (2022a)](https://tayshagtx.com/wp-content/uploads/ASGCT-2022-Safety-and-Biodistribution-Assessment-in-Non-Human-Primates-NHP-of-a-miniMECP2-AAV9-Vector-for-Gene-Replacement-Therapy-of-Rett-Syndrome.pdf)

> “A truncated MeCP2 protein retaining the essential methyl-CpG-binding domain (MBD) and the transcriptional repressor NCoR/SMRT interaction domain (NID) restored a normal phenotype in Mecp2-/Y mice and showed comparable functionality to full-length MeCP2”

Source: [Haque et al. (2026b)](https://tayshagtx.com/wp-content/uploads/ASGCT-Superior-expression-of-self-complementary-AAV-and-comparable-functionality-of-mini-and-full-length-MECP2-support-the-design-of-TSHA-102-gene-therapy-for-Rett-syndrome.pdf)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Transgene and protein expression: self-complementary compared with single-stranded AAV9 in Rett model cells

> “When looking at MeCP2 expression in RTT model cells, the scAAV9 vector (TSHA-102) produced up to 30-fold more MeCP2 protein than the ssAAV9 vector (ssAAV9-FL-MECP2), which expressed an insignificant amount of MeCP2 protein”
> “Using a GFP model transgene in RTT model cells, scAAV9 expressed ~30-fold more GFP transgene and GFP protein compared with ssAAV9, for which expression was negligible”

Source: [Haque et al. (2026b)](https://tayshagtx.com/wp-content/uploads/ASGCT-Superior-expression-of-self-complementary-AAV-and-comparable-functionality-of-mini-and-full-length-MECP2-support-the-design-of-TSHA-102-gene-therapy-for-Rett-syndrome.pdf)

<a id="topic-2.1.2.6.2-2"></a>

###### Functional comparison of mini-MeCP2 and full-length MeCP2 protein

> “mini-MeCP2 and FL-MeCP2 both achieved comparable, stable expression in neuronal cells when transfected with equimolar amounts of plasmid”
> “mini-MeCP2 and FL-MeCP2 proteins showed similar half-lives in the RTT model cells (12 h vs 9 h, respectively; Figure 5A), indicating comparable steady-state abundance and protein synthesis rates”
> “Both proteins inhibited DNMT3 activity in a dose-responsive manner, with similar levels of inhibition observed”

Source: [Haque et al. (2026b)](https://tayshagtx.com/wp-content/uploads/ASGCT-Superior-expression-of-self-complementary-AAV-and-comparable-functionality-of-mini-and-full-length-MECP2-support-the-design-of-TSHA-102-gene-therapy-for-Rett-syndrome.pdf)

<a id="topic-2.1.2.6.2-3"></a>

###### Genotype-dependent expression attributed to miRARE in Rett model cells

> “Protein levels were approximately 3.5- to 4-fold higher in RTT model cells compared with WT cells, consistent with miRARE-driven genotypic regulation of expression”
> “Almost no effect on biomolecule dysregulation was observed in WT background (dysregulated 1 and 8 for mini-MeCP2 and FL-MeCP2, respectively), suggesting no off-target activities in WT background as expected due to miRARE”

Source: [Haque et al. (2026b)](https://tayshagtx.com/wp-content/uploads/ASGCT-Superior-expression-of-self-complementary-AAV-and-comparable-functionality-of-mini-and-full-length-MECP2-support-the-design-of-TSHA-102-gene-therapy-for-Rett-syndrome.pdf)

<a id="topic-2.1.2.6.2-4"></a>

###### miRARE silencing of transgene expression in cultured cell lines

> “In MECP2–/– 2v6.11 cells, miniMeCP2 protein from the pTSHA102miRARE plasmid accumulated at a mean level ~2.3-fold greater than in parental 2v6.11 cells”
> “A 49% increase in miniMECP2 mRNA”
> “A 197% increase miniMeCP2 protein.”

Source: [Haque et al. (2023)](https://tayshagtx.com/wp-content/uploads/The-microRNA-responsive-autoregulatory-element-from-TSHA-102-for-Rett-Syndrome-modulates-therapeutic-transgene-expression-in-response-to-cellular-MeCP2-in-mouse-and-human-cell-lines.pdf)

<a id="topic-2.1.2.6.2-5"></a>

###### Survival, weight, and behavior after intracerebroventricular dosing in neonatal Mecp2 knockout mice

> “TSHA-102-treated KO mice (n=13) survived a median 36.0 weeks, representing a significant (p<0.0001) >4-fold extension of their lifespan versus vehicle-treated KO mice”
> “In WT animals, TSHA-102 treatment showed no toxicity, relative to vehicle treatment.”
> “Onset of severely abnormal gait (e.g., tremor when feet are lifted; backward walking; hopping) was significantly delayed from mean 8 weeks to 20 weeks”

Source: [Okposo et al. (2023)](https://tayshagtx.com/wp-content/uploads/A-Human-ready-Regulated-AAV9miniMECP2-miRARE-Gene-Therapy-TSHA-102-Improves-Survival-Weight-and-Behavior-After-Intracerebroventricular-ICV-Dosing-in-the-Neonatal-Knockout-Rett-RTT-Mouse-Model.pdf)

<a id="topic-2.1.2.6.2-6"></a>

###### Efficacy of the human-ready construct in Mecp2 knockout mice

> “In KO mice, TSHA-102 improved respiration, weight, and survival across multiple doses and treatment ages.”
> “Viral genomic DNA and miniMECP2 mRNA were present in the CNS. MiniMeCP2 protein expression was higher in the KO spinal cord compared to the brain.”
> “In female mice, TSHA-102 permitted survivals that were similar to those of vehicle-treated controls.”
> “In all, these pivotal data helped to support the regulatory approval to initiate a clinical trial for TSHA-102 in RTT patients”

Source: [Sadhu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10815157/)

<a id="topic-2.1.2.6.2-7"></a>

###### miRARE and the safety of high-dose miniMECP2 gene therapy in Rett mice

> “However, controlling deleterious overexpression of MECP2 remains the critical unmet obstacle towards a safe and effective gene therapy approach for Rett syndrome.”
> “The data provided herein show that insertion of miRARE into the miniMECP2 gene expression cassette greatly improved the safety of miniMECP2 gene transfer without compromising efficacy.”
> “Importantly, this built-in regulation system does not require any additional exogenous drug application, and no miRNAs are expressed from the transgene cassette.”

Source: [Sinnett et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8783608/)

<a id="topic-2.1.2.6.2-8"></a>

###### Nonclinical toxicology: single intrathecal dose in rats

> “No TSHA-102 mortality and no adverse TSHA-102-related clinical observations occurred.”
> “Microscopic evaluations (through Day 92) revealed a low incidence of minimal to mild, rarely moderate, axonal degeneration in the sciatic, tibial and sural nerves as well as nerve fibers associated with the DRG in all groups, including the controls.”
> “No apparent TSHA-102 dose association in the incidence or severity of the microscopic changes in the nerves.”
> “At Week 25, there were statistically significant reductions in NCV in mid-dose male and females, and high-dose males compared to control animals (Figure 2A).”

Source: [Prasad et al. (2022b)](https://tayshagtx.com/wp-content/uploads/Safety-Assessment-of-High-Dose-miniMECP2-AAV9-Gene-Replacement-Therapy-TSHA-102-for-Rett-Syndrome-in-Rats.pdf)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Route: delivery into cerebrospinal fluid and systemic exposure

> “Delivery of recombinant adeno-associated virus serotype 9 (rAAV9) into cerebrospinal fluid bypasses the blood–brain barrier and can permit efficient brain tissue transduction.”
> “As with intracisterna magna (ICM) or intra-cerebroventricular (ICV) instillation, IT delivery bypasses the blood–brain barrier, reduces vector load in systemic circulation, and minimizes risk of interference of pre-existing anti-AAV antibodies”
> “Uniquely, it offers the possibility of outpatient treatment with no specialized surgical equipment.”

Source: [Haque et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13167494/)

<a id="topic-2.1.2.6.3-2"></a>

###### Biodistribution of TSHA-102 in nonhuman primate brain and spinal cord after lumbar intrathecal infusion

> “CNS biodistribution showed generally similar vector genome levels in all CNS tissues tested, with a low value observed at the 90-day point for the cervical spinal cord”
> “Across four NHP biodistribution studies, at times ranging from 1 month to 1 year post-treatment, lumbar IT administration led to widespread, stable, and generally uniform vector genome levels throughout the brain and spinal cord.”
> “Across five NHP biodistribution studies, rAAV9 DNA was quantifiable in all brain and CNS tissues examined, irrespective of RoA (IT versus ICM) or time post-necropsy, at typical levels exceeding 1 vg copy per brain cell at the highest doses.”

Source: [Haque et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13167494/)

<a id="topic-2.1.2.6.3-3"></a>

###### Comparison of lumbar intrathecal and intracisterna magna delivery

> “At comparable doses and times, IT and ICM delivery led to widespread and consistent distribution of vector genomes, approximating 1 vg/diploid host genome throughout the brain at the higher doses tested.”
> “The ratio of ICM to lumbar IT vector biodistribution in various brain and spinal cord tissues ranged from <1 (temporal lobe) to ~5 (cerebellum).”

Source: [Haque et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13167494/)

<a id="topic-2.1.2.6.3-4"></a>

###### Dose dependence and change over time in brain vector genome levels

> “Comparing TSHA-102 versus TSHA-105 data, both with lumbar IT delivery, the four-fold increase in input dose with TSHA-105 was associated with a ~2.5-fold increase in vector genome levels detected in brain tissues; this difference was seen at both necropsy time points.”
> “This analysis also indicated higher brain vector genome levels in Day ≥180 necropsy samples, relative to Day 90 samples, in animals that had been treated by lumbar IT dosing.”

Source: [Haque et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13167494/)

<a id="topic-2.1.2.6.3-5"></a>

###### Limitations reported for the lumbar intrathecal route

> “However, some studies have suggested the lumbar IT route leads to limited transduction of brain tissues”
> “The fact that these studies were conducted separately, according to different protocols, limits the precision of any quantitative claims that can be made for rAAV9 biodistribution from this data set”

Source: [Haque et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13167494/)

<a id="topic-2.1.2.6.3-6"></a>

###### Administration and monitoring conditions of the nonclinical biodistribution studies

> “IT injection was to the L4-5 or L5-6 intervertebral space, with the needle tip angled slightly cranially.”
> “Injections (2.5 mL total volume) were performed with animals prone or recumbent, not in the Trendelenburg position.”
> “No immunosuppression was used.”

Source: [Haque et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13167494/)

<a id="topic-2.1.2.6.3-7"></a>

###### Detection of vector DNA in all tissues analyzed at 90 and 180 days

> “At 90 days and 180 days, TSHA-102 (lumbar IT) DNA was detected in all tissues analyzed post-lumbar IT infusion and biodistribution was consistent across all tissues (Figure 3)”
> “Following lumbar IT delivery, vector DNA levels were dose-dependent; the 4-fold dose increase was associated with a 1.5–2.5-fold vector copy number increase in brain tissues (Figure 5)”

Source: [Haque et al. (2025)](https://tayshagtx.com/wp-content/uploads/rAAV9-Vector-Biodistribution-in-Brain-and-Spinal-Cord-via-Lumbar-Intrathecal-Infusion-in-Nonhuman-Primates-NHP-Assessing-the-Administration-Route-Leveraged-in-TSHA-102-Rett-Syndrome-Clinical-Trials.pdf)

<a id="topic-2.1.2.6.3-8"></a>

###### Pharmacokinetic measurements in humans

No evidence found.

Additional sources: [Haque et al. (2024)](https://tayshagtx.com/wp-content/uploads/Broad-CNS-Biodistribution-of-AAV9-based-Gene-Therapies-Delivered-by-Intrathecal-Lumbar-Puncture-in-Non-Human-Primates.pdf)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Age range of the pivotal cohort: females aged 6 to under 22 years

> “Females between the ages of 12 and <22 in Part A (closed) and females between the ages of 6 and <22 in Part B (pivotal cohort).”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-2.1.2.8-2"></a>

###### Children aged 5 to 8 years: REVEAL Pediatric trial

> “Participant is between ≥5 to ≤8 years of age at the time of consent.”

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-2.1.2.8-3"></a>

###### Children aged over 2 to under 4 years: ASPIRE trial

> “Pediatric females between the ages of 2 and less than 4 years old.”
> “The primary objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of a single intrathecal (IT) dose of TSHA-102 in pediatric females with typical Rett syndrome.”

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-2.1.2.8-4"></a>

###### Extrapolation of efficacy to children aged 2 to under 6 years

> “A minimum of three months of ASPIRE safety data will be included in the planned BLA submission, while efficacy in the 2 to <6-year-old population will be extrapolated from data collected in the REVEAL pivotal trial”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.1.2.8-5"></a>

###### Paediatric subsets and studies agreed in the European Union paediatric investigation plan

> “From birth to less than 18 years of age”
> “Open-label, randomized, 2-part study including a dose-escalation (Part A) and dose expansion (Part B) to evaluate the safety, efficacy, and durability of a single intrathecal dose of TSHA-102 in female children from 2 to less than 9 years of age with Rett syndrome with a documented MECP2 loss-of-function gene mutation.”
> “Deferral for one or more measures contained in the paediatric investigation plan: Yes”
> “Date of completion of the paediatric investigation plan: By December 2033”

Source: [EMA paediatric investigation plan decision (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232894-ema-decision-14-april-2025-agreement-paediatric-investigation-plan-granting-deferral-adeno-associated-viral-vector-serotype-9-containing-human-mecp2-gene_en.pdf-0)

<a id="topic-2.1.2.8-6"></a>

###### Sex: the trials enrolled females

> “The REVEAL Pivotal Trial is a single-arm, open-label study evaluating the efficacy and safety of TSHA-102 in females with Rett syndrome, with each patient serving as their own control.”

Source: [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/)

> “Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-2.1.2.8-7"></a>

###### Participants requiring invasive ventilatory support were excluded

> “Participant requires invasive ventilatory support.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

> “Participant requires non-invasive and invasive ventilatory support.”
> “Participant has acute or chronic hepatitis B or C infections.”

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-2.1.2.8-8"></a>

###### Pregnancy, lactation, renal impairment, and hepatic impairment

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Lonimecgene renparvovec

<a id="topic-2.1.2.9.1-1"></a>

###### Immunoprophylaxis schedule and taper in the trial protocols

> “Immunoprophylaxis will begin at Day –7 and will be tapered from Week 17 to Week 25 (oral prednisolone) and starting from Week 38 (sirolimus).”

Source: [Devidze et al. (2023)](https://tayshagtx.com/wp-content/uploads/Design-of-the-REVEAL-Pediatric-study-of-TSHA-102-gene-therapy-for-Rett-Syndrome.pdf)

<a id="topic-2.1.2.9.1-2"></a>

###### Vaccination required before the immunosuppression regimen

> “Participant must be up to date with all relevant local vaccination requirements, with last vaccination dose received at least 42 days prior to the start of the immunosuppression regimen.”
> “Participant has contraindications for IT administration of TSHA-102 or lumbar puncture procedure, other medical conditions, or contraindications to any medications required for IT administration.”

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-2.1.2.9.1-3"></a>

###### Pre-existing anti-AAV9 antibodies in the nonclinical studies

> “Serum AAV9 neutralizing (nAb) antibodies, were assessed before treatment. Animals with detectable nAbs (e.g., titers ≥1:10) were preferentially chosen for diluent-only treatment, whereas those with low or undetectable nAbs could receive rAAV9 treatment.”

Source: [Haque et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13167494/)

<a id="topic-2.1.2.9.1-4"></a>

###### Clinical pharmacokinetic drug interaction studies

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Lonimecgene renparvovec on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Dose levels evaluated in the REVEAL Part A trials

> “Two of the participants received the low dose (5.7×10¹⁴ vg) of TSHA-102 and four of the participants received the high dose (1×10¹⁵ vg) of TSHA-102.”

Source: [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/)

> “TSHA-102 Dose Level 1: 5.7×10¹⁴ total vector genomes (vg).”
> “TSHA-102 Dose Level 2: 1.0×10¹⁵ total vector genomes (vg)”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-2.1.2.10.1-2"></a>

###### Dose administered to the pivotal cohort

> “TSHA-102 at Selected Dose (Dose Level 2): 1.0 × 10¹⁵ total vector genomes (vg)”
> “Participants receive a single intrathecal (IT) administration of TSHA-102 at Dose Level 2 (1.0 × 10¹⁵) (fully enrolled, 17 participants).”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-2.1.2.10.1-3"></a>

###### Dose in the ASPIRE trial adjusted for brain volume

> “Participants receive a single intrathecal (IT) administration of TSHA-102 at 1.0 × 10¹⁵ total vector genomes (vg) adjusted for the participant's brain volume.”

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-2.1.2.10.1-4"></a>

###### Single administration

> “TSHA-102 is a one-time intrathecal (IT) administration.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-2.1.2.10.1-5"></a>

###### Dose escalation objective in the phase 1/2 trials

> “Evaluate two dose levels to, if possible, establish maximum administered dose (MAD) or maximum tolerated dose (MTD)”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Pharmaceutical form and route in the European Union paediatric investigation plan

> “Pharmaceutical form(s): Solution for infusion Route(s) of administration: Intrathecal use”

Source: [EMA paediatric investigation plan decision (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232894-ema-decision-14-april-2025-agreement-paediatric-investigation-plan-granting-deferral-adeno-associated-viral-vector-serotype-9-containing-human-mecp2-gene_en.pdf-0)

<a id="topic-2.1.2.10.2-2"></a>

###### Delivery into the cerebrospinal fluid

> “The vector is delivered directly to the cerebrospinal fluid via intrathecal administration, which facilitates optimal biodistribution and cell transduction within key regions of the CNS.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.1.2.10.2-3"></a>

###### Procedure and care setting

> “We use intrathecal administration, which directly delivers our gene therapies to the cerebrospinal fluid to facilitate biodistribution and cell transduction within key regions of the CNS. The procedure is routinely performed in an outpatient setting, and compared to intravenous administration, it allows for a lower dose of the therapy.”

Source: [Taysha Gene Therapies our science page](https://tayshagtx.com/our-science/)

> “Leads to widespread and consistent biodistribution across the brain and spinal cord using a routine, minimally invasive procedure with potential for outpatient administration”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-2.1.2.10.2-4"></a>

###### Administration of the first dose given in the clinical program

> “Taysha-102 was injected intrathecally in the lumbar spine, with general anesthesia.”
> “The Participant was discharged on Day 1.”

Source: [Rossignol et al. (2023)](https://tayshagtx.com/wp-content/uploads/Early-safety-and-efficacy-observations-following-the-first-use-of-TSHA-102-gene-therapy-in-a-patient-with-Rett-Syndrome.pdf)

<a id="topic-2.1.2.10.2-5"></a>

###### Positioning and monitoring after dosing

> “Patients were placed in Trendelenburg position post-dosing. Regular safety monitoring includes clinical and laboratory evaluations.”

Source: [Rossignol et al. (2024b)](https://tayshagtx.com/wp-content/uploads/TSHA-102-gene-therapy-for-Rett-syndrome-First-cohort-data-from-the-REVEAL-Adolescent-Adult-and-Pediatric-studies.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Access during development: clinical trial participation only

> “Access to Taysha’s investigational products is currently available only through participation in a clinical trial for patients who meet the applicable eligibility criteria. At this stage of development, Taysha does not offer *Expanded Access to its investigational therapies.”

Source: [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/)

<a id="topic-2.1.2.11-2"></a>

###### Commercial manufacturing and supply agreement with Catalent

> “Building on a partnership that has supported the development of TSHA-102 since 2020, the agreement secures long-term commercial manufacturing capacity and a scalable supply framework to support a potential commercial launch and future demand.”
> “Catalent will provide GMP manufacturing and commercial supply of TSHA-102 at its FDA-licensed commercial gene therapy facility in Harmans, Maryland, leveraging its experience across more than 90 gene therapy programs, including multiple commercial products.”

Source: [Taysha Gene Therapies Catalent commercial manufacturing announcement (2026)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-and-catalent-expand-strategic-partnership)

<a id="topic-2.1.2.11-3"></a>

###### Commercial-scale manufacturing process qualification

> “Completed BLA-Enabling Process Performance Qualification (PPQ) Campaign for TSHA-102.”
> “The final TSHA-102 commercial manufacturing process consistently achieved a single-digit empty capsid percentage, an important indicator of product quality that contributes to patient safety. The PPQ results also demonstrate the process consistency and scalability required to support potential commercial demand.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-2.1.2.11-4"></a>

###### Care setting: intrathecal administration with outpatient potential

> “TSHA-102 delivered intrathecally, a minimally invasive procedure with outpatient potential, enabling broad, scalable access”

Source: [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm)

<a id="topic-2.1.2.11-5"></a>

###### Market access and payer research

> “Completed payer research to inform market access planning, which demonstrated strong support for TSHA-102’s significant value proposition and reimbursement potential, including:”
> “TSHA-102 was viewed as a high-value therapy due to its transformative disease-modifying potential in a population with high unmet need, combined with the convenience of a one-time IT administration that can be performed in an outpatient setting”
> “Strong efficacy, safety and durability are expected to drive coverage and reimbursement, with durable functional benefits serving as the key value determinant in this high unmet need setting”

Source: [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm)

<a id="topic-2.1.2.11-6"></a>

###### Commercial inventory build

> “Company raised an additional $50.0 million in gross proceeds by utilizing its at-the-market equity offering program, with proceeds intended to support a potential commercial inventory build in 2027.”

Source: [Taysha Gene Therapies full-year 2025 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115177/d46409dex991.htm)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Immunoprophylaxis given with the vector: sirolimus and oral prednisolone

> “Immunoprophylaxis was initiated on Day –7 and administered at the study site in Montréal”
> “Sirolimus (blood trough: 4 – 8 ng/mL)”
> “Oral prednisolone.”

Source: [Rossignol et al. (2023)](https://tayshagtx.com/wp-content/uploads/Early-safety-and-efficacy-observations-following-the-first-use-of-TSHA-102-gene-therapy-in-a-patient-with-Rett-Syndrome.pdf)

<a id="topic-2.1.2.12-2"></a>

###### Immunosuppression initiation relative to dosing

> “Following immunosuppression initiation at Day –7”

Source: [Rossignol et al. (2024b)](https://tayshagtx.com/wp-content/uploads/TSHA-102-gene-therapy-for-Rett-syndrome-First-cohort-data-from-the-REVEAL-Adolescent-Adult-and-Pediatric-studies.pdf)

<a id="topic-2.1.2.12-3"></a>

###### Completion of the steroid and sirolimus tapers in the first participants treated

> “The first adult patient sustained improvements at week 52 post-treatment after the completion of her steroid and sirolimus taper”
> “The second adult patient showed sustained improvements following the completion of her steroid taper at week 25 post-treatment”

Source: [Taysha Gene Therapies low dose cohort data announcement (2024)](https://www.sec.gov/Archives/edgar/data/1806310/000119312524163050/d851091dex991.htm)

<a id="topic-2.1.2.12-4"></a>

###### Adverse events attributed to the immunosuppressive regimen

> “The most common AE overall was vomiting (5 TEAEs), a known risk of sirolimus.”
> “Has experienced irritability thought to be secondary to immunosuppression.”

Source: [Rossignol et al. (2024b)](https://tayshagtx.com/wp-content/uploads/TSHA-102-gene-therapy-for-Rett-syndrome-First-cohort-data-from-the-REVEAL-Adolescent-Adult-and-Pediatric-studies.pdf)

<a id="topic-2.1.2.12-5"></a>

###### Antiseizure medications during follow-up

> “Phenobarbital was added to regimen at Week 4 due to event of increased seizures.”
> “Stable seizure events with lower levels of anti-seizure medication, relative to Baseline”

Source: [Rossignol et al. (2024b)](https://tayshagtx.com/wp-content/uploads/TSHA-102-gene-therapy-for-Rett-syndrome-First-cohort-data-from-the-REVEAL-Adolescent-Adult-and-Pediatric-studies.pdf)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Lonimecgene renparvovec on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Comparator landscape as stated by the sponsor

> “Trofinetide was approved by the FDA in March 2023 for the treatment of Rett Syndrome. We are aware that our competitors are developing product candidates for the treatment of diseases that our product candidates will target. With respect to TSHA-102, we are aware that Neurogene has a clinical stage gene therapy program for the treatment of Rett syndrome.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.1.2.14-2"></a>

###### Trofinetide: approved indication and dosing

> “DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.”
> “The recommended dosage of DAYBUE or DAYBUE STIX is based on patient weight as shown in Table 1. Administer DAYBUE or DAYBUE STIX orally or via gastrostomy (G) tube twice daily, in the morning and evening, with or without food.”

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

<a id="topic-2.1.2.14-3"></a>

###### Trofinetide: mechanism of action and tolerability

> “The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown.”
> “85% of patients treated with DAYBUE experienced diarrhea.”
> “In those treated with DAYBUE, 49% either had persistent diarrhea or recurrence after resolution despite dose interruptions, reductions, or concomitant antidiarrheal therapy.”
> “In Study 1, vomiting occurred in 29% of patients treated with DAYBUE and in 12% of patients who received placebo”

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

###### NGN-401: construct, regulation, and route of administration

> “NGN-401 is an investigational AAV9 gene therapy in late-stage clinical development as a potential best-in-class, one-time treatment for Rett syndrome.”
> “NGN-401 is delivered through intracerebroventricular administration to achieve the broadest targeting directly to the brain and nervous system based on nonclinical biodistribution data.”

Source: [Neurogene third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000064/ngne_3qye26earningsrelease.htm)

<a id="topic-2.1.2.14-5"></a>

###### NGN-401: registrational trial and expected data

> “Anticipate reporting topline data from the Embolden™ registrational trial in the second half of 2027”
> “Neurogene elected to include all 25 participants dosed in the primary efficacy analysis.”
> “The corresponding threshold for success to reject the null hypothesis is 9 of 25 participants (36%).”
> “NGN-401 at the 1E15 vg dose has been generally well-tolerated in the Phase 1/2 trial and Embolden (N=35) as of November 8, 2026”

Source: [Neurogene third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000064/ngne_3qye26earningsrelease.htm)

<a id="topic-2.1.2.14-6"></a>

###### NGN-401: registry record of the Embolden trial

> “A Baseline-Controlled, Open-Label, Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy, Safety, and Tolerability of NGN-401 in Subjects With Rett Syndrome (Embolden)”
> “NGN-401 is a non-replicating, recombinant AAV9 carrying a full length human MECP2 transgene.”

Source: [ClinicalTrials.gov NCT05898620](https://clinicaltrials.gov/study/NCT05898620)

<a id="topic-2.1.2.14-7"></a>

###### Published comparison of TSHA-102 and NGN-401

| Feature | TSHA-102 | NGN-401 |
| --- | --- | --- |
| MECP2 construct | “Truncated miniMECP2 (MBD + NID domains only)” | “Full-length human MECP2” |
| Regulatory system | “miRARE (endogenous miRNA-responsive)” | “EXACT (synthetic miRNA feedforward loop)” |
| AAV type | “Self-complementary AAV9” | “Standard single-stranded AAV9” |
| Administration route | “Intrathecal lumbar puncture” | “Intracerebroventricular (ICV)” |
| Procedural complexity | “Moderate (lumbar puncture)” | “Higher (neurosurgical ICV access)” |
| CNS biodistribution | “Moderate (based on IT delivery)” | “Superior (10–100 × higher in preclinical NHP studies)” |
| Safety profile to date | “Favorable; no SAEs or DLTs” | “Favorable at low doses; high-dose hyperinflammatory fatality” |

Source: [Samanta (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12864443/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Clinical definition

> “Rett syndrome (RTT) is a severe, progressive, neurodevelopmental disorder, which affects predominantly females. In most cases, RTT is associated with pathogenic variants in MECP2. MeCP2, the protein product of MECP2, is known to regulate gene expression and is highly expressed in the brain. RTT is characterized by developmental regression of spoken language and hand use that, with hand stereotypies and impaired ambulation, constitute the four core diagnostic features.”

Source: [Gold et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39511247/)

> “Classic Rett syndrome, a progressive neurodevelopmental disorder primarily affecting girls, is characterized by apparently normal psychomotor development during the first six to 18 months of life, followed by a short period of developmental stagnation, then rapid regression in language and motor skills, followed by long-term stability. During the phase of rapid regression, repetitive, stereotypic hand movements replace purposeful hand use.”

Source: [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/)

> “The clinical picture associated with typical RTT is defined by a regression of purposeful hand use and spoken language, with the development of gait abnormalities and hand stereotypies. After the period of regression, a stage of stabilization and potentially even improvement ensues, with some individuals partially regaining skills.”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

<a id="topic-2.2.1.1-2"></a>

###### Sponsor description of the disease

> “Rett syndrome, a rare progressive neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene encoding methyl CpG-binding protein 2, or MeCP2, which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy.”
> “Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.2.1.1-3"></a>

###### Original descriptions by Rett and by Hagberg

> “Rett Syndrome (RTT, MIM 312750), an X-linked neurodevelopmental condition characterized by loss of spoken language and hand use with the development of distinctive hand stereotypies, was originally described in the 1960’s by Andreas Rett”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

> “Believing the symptoms to be consistent with a metabolic disorder, he called it ‘cerebroatrophic hyperammonaemia’ in a 1966 German publication”

Source: [Kyle et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5830535/)

> “Thirty-five patients, exclusively girls, from three countries had a uniform and striking progressive encephalopathy.”
> “The condition is similar to a virtually overlooked syndrome described by Rett in the German literature.”

Source: [Hagberg et al. (1983)](https://pubmed.ncbi.nlm.nih.gov/6638958/)

<a id="topic-2.2.1.1-4"></a>

###### Variant (atypical) Rett syndrome

> “Variant Rett syndrome. Females with variant Rett syndrome exhibit a broader spectrum of clinical features than those observed in classic Rett syndrome. At the more severe end of the spectrum, development is delayed from very early infancy; congenital hypotonia and infantile spasms are also seen. At the milder end of the spectrum, regression is less dramatic and intellectual disability is much less severe; some speech may be preserved.”

Source: [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/)

<a id="topic-2.2.1.1-5"></a>

###### Genetic cause: MECP2 variants

> “Our study reports the first disease-causing mutations in RTT and points to abnormal epigenetic regulation as the mechanism underlying the pathogenesis of RTT.”

Source: [Amir et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10508514/)

> “Using a battery of modern mutation detection assays, mutations in MECP2 can be found in 95–97% of individuals with typical RTT”
> “Importantly, even using the best methodologies, 3–5% of individuals who strictly meet clinical criteria for RTT do not have an identified mutation in MECP2, indicating that a mutation in this gene is not required to make the diagnosis of typical RTT”
> “The situation is more dramatic in atypical cases, with only 50–70% having identified mutations in MECP2”
> “Because MECP2 mutations are neither necessary nor sufficient to make the diagnosis of RTT, RTT remains a clinical diagnosis.”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

<a id="topic-2.2.1.1-6"></a>

###### Variants in other genes in atypical presentations

> “Recent work has found mutations in different loci associated with these variant forms, with mutations in CDKL5 found in early seizure variant cases”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

<a id="topic-2.2.1.1-7"></a>

###### MECP2-related disorders nomenclature

> “We propose that all individuals with clinical disorders and MECP2 mutations be called MECP2-related disorders, which includes RTT and other neurological conditions associated with MECP2 mutations.”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

<a id="topic-2.2.1.1-8"></a>

###### De novo occurrence and X-linked inheritance

> “MECP2 disorders are inherited in an X-linked manner. More than 99% are simplex cases (i.e., a single occurrence in a family), resulting from a de novo pathogenic variant or possibly from inheritance of the pathogenic variant from a parent who has germline mosaicism. Rarely, a MECP2 variant may be inherited from a heterozygous mother in whom favorable skewing of X-chromosome inactivation results in minimal to no clinical findings. When the mother is a known heterozygote, the risk to her offspring of inheriting the MECP2 variant is 50%.”

Source: [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/)

> “Although Rett syndrome is a genetic disorder, less than 1% of recorded cases are passed from one generation to the next. Most cases are spontaneous, which means the mutation occurs randomly.”

Source: [NINDS](https://www.ninds.nih.gov/health-information/disorders/rett-syndrome)

<a id="topic-2.2.1.1-9"></a>

###### Paternal origin of de novo variants and female predominance

> “RTT almost exclusively affects female offspring and, in 99.5% of all cases, is sporadic and due to de novo mutations in the MECP2 gene.”
> “We analyzed the parental origin of MECP2 mutations in sporadic cases of RTT, by analysis of linkage between the mutation in the MECP2 gene and intronic polymorphisms in 27 families with 15 different mutations, and we found a high predominance of mutations of paternal origin in 26 of 27 cases (P<.001).”
> “We conclude that de novo mutations in RTT occur almost exclusively on the paternally derived X chromosome and that this is most probably the cause for the high female:male ratio observed in patients with RTT.”

Source: [Trappe et al. (2001)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1226090/)

<a id="topic-2.2.1.1-10"></a>

###### Males with MECP2 variants

> “Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities. Death often occurs before age two years.”

Source: [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/)

> “To enhance understanding of the phenotypic spectrum present in these individuals, we identified thirty males with MECP2 mutations in the RTT Natural History Study databases. A wide phenotypic spectrum was observed, ranging from severe neonatal encephalopathy to cognitive impairment. Two males with a somatic mutation in MECP2 had classic RTT.”
> “careful review of the clinical history determined that an additional 12/28 subjects met criteria for atypical RTT, but with more severe clinical presentation and course, and less distinctive RTT features, than females with RTT, leading to the designation of a new diagnostic entity, Male RTT Encephalopathy.”

Source: [Neul et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6488031/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Rett syndrome

<a id="topic-2.2.1.2.1-1"></a>

###### Australia: cumulative incidence by age, Australian Rett Syndrome Database

> “the cumulative incidence was 1.09 per 10,000 females by 12 years of age. The cumulative incidence by the age of 5 years increased from .39 per 10,000 in the 1980 to 1984 cohort to .76 per 10,000 in birth cohorts beyond 1984.”

Source: [Laurvick et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16615965/)

<a id="topic-2.2.1.2.1-2"></a>

###### Australia: cumulative risk of diagnosis and birth prevalence, females born 1976 to 2006

> “The population-based Australian Rett Syndrome Database was used to identify a total of 349 verified Rett syndrome females born 1976-2006 and diagnosed 1982-2008.”
> “The cumulative risk of diagnosis had almost doubled by 32 y of age [1/8,905 or 11.23 per 100,000 person-years (95% CI, 10.03–12.45)] in comparison with 5 y of age [1/15,361 or 6.51 per 100,000 person-years (95% CI, 5.65–7.39)].”
> “The birth prevalence varied by birth year (Table 2), peaking for those born in the early to mid 1990s.”

Source: [Fehr et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3152673/)

| Year of birth | Number of cases | Number of cases per 100,000 female births (95% CI) |
| --- | --- | --- |
| Overall (1976-2006) | “349” | “9.37 (8.41-10.41)” |

Source: [Fehr et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3152673/)

<a id="topic-2.2.1.2.1-3"></a>

###### France: incidence of Rett syndrome with an MECP2 variant

> “The present study, based on a large cohort of 424 patients with Rett syndrome, found that the incidence of this disease with a MECP2 mutation varied between 0.43 to 0.71 per 10,000 females.”
> “Given that this is a minimum incidence because complete inventory was not possible, this study of patients with Rett syndrome reinforces the fact that the great majority of patients with Rett syndrome have a MECP2 mutation.”

Source: [Bienvenu et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16647997/)

<a id="topic-2.2.1.2.1-4"></a>

###### Serbia: incidence per female live births, 1981 to 2012

> “From 1981 to 2012, RTT has been diagnosed in 102 girls in Serbia. Incidence of RTT in Serbia is estimated at 0.586:10,000 female live births.”

Source: [Sarajlija et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25571926/)

<a id="topic-2.2.1.2.1-5"></a>

###### United States: annual incidence of diagnosis in claims data, 2018 and 2019

> “Overall, the annual incidence of RTT in this dataset was an estimated 0.34 and 0.23 per 10,000 enrollees in 2018 and 2019, respectively (Table 2). Among female patients, the annual incidence was 0.43 and 0.31 per 10,000 female enrollees in 2018 and 2019, respectively, while among male patients, it was 0.22 and 0.13 per 10,000 male enrollees, respectively. Stratified by age, incidence estimates per 10,000 enrollees for the pediatric population in 2018 and 2019 were 1.40 and 1.25, respectively, for ages 0–4 years; 1.53 and 0.92 for ages 5–10 years; and 1.00 and 0.67 for ages 11–17 years (Table 3).”
> “Annual incidence was calculated as the proportion of patients newly diagnosed with RTT among the total number of at-risk patients at the start of the study period. A minimum 6-month washout period was used to ensure at-risk enrollees and incident cases did not have a RTT diagnosis.”

Source: [May et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10071755/)

<a id="topic-2.2.1.2.1-6"></a>

###### Canada: incident cases in Ontario administrative data, 2017 to 2023

> “Incident cases were identified between September 2017 and August 2023, while prevalent cases were captured from April 2002 to August 2023.”
> “From September 2017 to August 2023, 57 incident cases and 257 prevalent cases were reported in Ontario.”

Source: [Bond et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41267498/)

> “According to sponsor-submitted information, there are approximately 8 to 12 incident cases diagnosed annually in Ontario.”

Source: [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Rett syndrome

<a id="topic-2.2.1.2.2-1"></a>

###### Global pooled prevalence in females: systematic review and meta-analysis

> “We conducted a search of PubMed, Embase, Web of Science, Cochrane Library, LILACS, and LIVIVO to retrieve studies published in English between Jan. 1, 2000, and June 30, 2021. Pooled prevalence with a 95% confidence interval (CI) was estimated using a random-effects meta-analysis based on a generalized linear mixed model with a logit link.”
> “Ten eligible studies were identified (all in females), with a combined sample size of 9.57 million women and 673 Rett syndrome cases. The pooled prevalence estimate (random effects) was 7.1 per 100,000 females (95% CI: 4.8, 10.5, heterogeneity p < 0.001). Despite greatly variable precision of estimation, all estimates were compatible with a prevalence range of approximately 5 to 10 cases per 100,000 females based on their respective 95% CIs.”
> “Study-specific prevalence estimates per 100,000 females (95% CI) ranged from 0.0 (0.0, 8.8) to 38.3 (4.6, 138.0), with a highly significant heterogeneity test (p < 0.001, I2 = 0.831).”
> “No studies that included patients with RTT older than 35 years were included.”

Source: [Petriti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9841621/)

<a id="topic-2.2.1.2.2-2"></a>

###### Worldwide prevalence per female births: reference estimates

> “The worldwide prevalence is 1:10,000-1:23,000 female births”

Source: [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/)

> “Rett syndrome (RTT) is a severe neurodevelopmental disease that affects approximately 1 in 10,000 live female births”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

<a id="topic-2.2.1.2.2-3"></a>

###### Australia: point prevalence by age group

> “The point prevalence of RTT in Australia on the 31st June 2009 was 8.6 per 100,000 females (95% CI 7.4-10.1) aged five to 18 years and 5.8 per 100,000 females (95% CI 4.8-6.9) aged 19 years to 32 years.”

Source: [Fehr et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3152673/)

> “The prevalence of RTT was .88 per 10,000 females in 5- to 18-year-olds”

Source: [Laurvick et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16615965/)

<a id="topic-2.2.1.2.2-4"></a>

###### France: prevalence in females aged 4 to 15 years

> “The data presented here indicate a prevalence of Rett syndrome of 0.558 per 10,000 females aged 4-15 years in France.”

Source: [Bienvenu et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16647997/)

<a id="topic-2.2.1.2.2-5"></a>

###### Serbia: prevalence in females younger than 19 years

> “We estimated the prevalence of RTT in population of females younger than 19 years at 1:8,439.”

Source: [Sarajlija et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25571926/)

<a id="topic-2.2.1.2.2-6"></a>

###### United States: annual prevalence of diagnosis in claims data, 2016 to 2019

> “The annual prevalence of RTT between November 1, 2016 and October 31, 2019 in this dataset ranged from 0.30–0.32 per 10,000 enrollees overall, with higher prevalence ranges observed among female than male patients (female: 0.45–0.52; male: 0.08–0.10; Table 1).”
> “Annual prevalence was calculated as the proportion of patients with a diagnosis of RTT among the total number of patients enrolled in the IQVIA Dx and LRx databases.”

Source: [May et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10071755/)

<a id="topic-2.2.1.2.2-7"></a>

###### United States, European Union, Japan, Canada, and Israel: trofinetide manufacturer estimates

> “Based on 2024 claims data, we estimate that approximately 6,000 people are diagnosed with Rett Syndrome in the U.S. We estimate a prevalent population of 6,000 to 9,000 people in the U.S.”
> “In the European Union, where we estimate a prevalent population of 9,000 to 12,000 Rett syndrome patients, we filed our marketing authorization application (MAA) with the European Medicines Agency (EMA) in January 2025.”
> “In Japan, where we estimate a prevalent population of 1,000 to 2,000 Rett syndrome patients, we are conducting a small Phase 3 study to support a future JNDA to that regulatory agency.”
> “In Canada, where we estimate a prevalent population of 600 to 900 Rett syndrome patients, Health Canada granted marketing authorization of DAYBUE in October 2024. In Israel, where we estimate a prevalent population of about 200 Rett syndrome patients, the Ministry of Health in Israel granted marketing authorization of DAYBUE in December 2025.”

Source: [Acadia Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm)

<a id="topic-2.2.1.2.2-8"></a>

###### United States, European Union, and United Kingdom: TSHA-102 sponsor estimate of the addressable population

> “The estimated addressable patient population with typical Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is between 15,000 and 20,000 patients in the United States, European Union and United Kingdom. Within the U.S. specifically, patient estimates range from 6,000 to 9,000 based on claims data and epidemiology data.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.2.1.2.2-9"></a>

###### Canada: estimated and diagnosed prevalence

> “It is estimated to affect 1 in 10,000 females aged 12 years and younger, with a worldwide prevalence of 1 in 20,000 to 1 in 40,000”
> “According to the sponsor, in Canada, the estimated prevalence is between 600 and 900 cases, based on the extrapolation of US epidemiological data, and around 220 to 240 prevalent cases are diagnosed in Ontario annually, based on assessments of Institute for Clinical Evaluative Sciences datasets”

Source: [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1)

> “In total, 246 RTT cases were indexed; 40% from central Ontario, 95% female, median age 21 years.”

Source: [Bond et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41267498/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Natural history: age at regression and onset of hand stereotypies

> “Age at onset of regression (Table 1A) occurred between 12 and 30 months in more than 80% of individuals, with 36.2% occurring between 12 and 18 months of age and 46.1% between 18 and 30 months.”
> “Stereotypies (Table 1B) began most frequently (55.6%) at 18–36 months, whereas 22.7% developed these from 12 to 18 months.”

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)

> “Developmental regression occurred in all Rett syndrome participants (median 18 months)”

Source: [Cutri-French et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8882337/)

<a id="topic-2.2.1.3-2"></a>

###### Natural history: trajectory of skill gain, loss, and regain

> “Loss of previously gained skills occurred in all skill domains, with highest frequency in fine motor and expressive language domains. For most skills, loss occurred early in life and within 2 years of gain, except for loss of gross motor skills which occurred at older ages and further from age of gain. Regain of lost skills was infrequent for most skills, occurred mainly before 6 years old, and within 2 years of loss. After 6 years old, the incidence of either gaining or regaining skills was low.”
> “The median age of skill loss was 3 years old or less for 46 of the 51 developmental skills (90%), and in 31 developmental skills, 95% of participants lost skills by 6 years old.”
> “After age 6 years it is unlikely that a skill not previously obtained will be gained or that a skill previously lost will be regained.”

Source: [Neul et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094048/)

<a id="topic-2.2.1.3-3"></a>

###### Natural history: course in women aged 40 years and older

> “Information was available on 30 women with a clinical diagnosis of Rett syndrome (RTT), of whom 24 were < 50 years. Twenty‐nine women were diagnosed with classic RTT and one with atypical RTT. Of 18 women tested for MECP2 mutations, pathogenic variants were identified in 14. There was little increase in severity over time.”
> “Some features of RTT improved with aging, for example, epilepsy, agitation, sleep, and hand stereotypies.”

Source: [Hryniewiecka-Jaworska et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11975466/)

<a id="topic-2.2.1.3-4"></a>

###### Survival: North American database of 1928 individuals

> “Earlier decennial cohorts had better survival than recent cohorts, most participants surviving into middle age. Comparing overall survival between typical and atypical RTT, those with typical RTT had greater mortality than those with atypical RTT across the observed lifespan (p<.0001).”
> “Among all participants studied, a total of 305 deaths (15.8%) had occurred as of January 1, 2006.”

Source: [Kirby et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2794941/)

<a id="topic-2.2.1.3-5"></a>

###### Survival: US Rett Syndrome Natural History Study

> “Among 1189 valid participants, 51 died (range 3.9–66.6 years) during the 9-year follow-up period.”
> “Survival for classic and atypical RTT was greater than 70% at 45 years.”
> “We can estimate, with 95% confidence, that at least 95% of the classic RTT population survive until age 20, 80% survive until age 35, and over 70% survive until age 50.”

Source: [Tarquinio et al. (2015b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4609589/)

<a id="topic-2.2.1.3-6"></a>

###### Survival: Australian Rett Syndrome Database, 20 years of follow-up

> “Using the Kaplan-Meier method, we estimated survival of individuals registered with the Australian Rett syndrome Database (ARSD) who had been followed for up to 20 years (n = 396).”
> “The conditional probability of survival was 77.6% (95% confidence interval (CI) 71.3, 82.8) at 20 years, 71.5% (95% CI 64.6, 77.3) at 25 years and 59.8% (95% CI 49.3,68.8) at 37 years (Figure 1).”

Source: [Anderson et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4078387/)

<a id="topic-2.2.1.3-7"></a>

###### Survival: Rett's original Austrian cohort compared with the Australian database

> “The median age at death was 13 years 4.8 months. The probability of survival up to the age of 25 years was 21%, compared with 71% in the Australian cohort (p<0.001).”

Source: [Freilinger et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20573179/)

<a id="topic-2.2.1.3-8"></a>

###### Causes of death

> “Most deaths were due to cardiorespiratory issues. Only one died due to severe malnutrition, scoliosis, and extreme frailty.”
> “Post-operative complications were a cause of death in a minority, following scoliosis surgery, ileostomy, and tonsillectomy. Epilepsy was cited as cause of death (without respiratory complications) in four classic RTT participants and one atypical RTT participant.”

Source: [Tarquinio et al. (2015b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4609589/)

> “Information on cause of death was available for 57 (82.6%) out of 69 females who were deceased. Lower respiratory tract infection (36.8% 21/57) was the most common cause of death, followed by aspiration/asphyxiation (31.6% 18/57), respiratory failure (14.0% 8/57) and seizure related illness (5.3% 3/57).”

Source: [Anderson et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4078387/)

<a id="topic-2.2.1.3-9"></a>

###### Sudden death: cardiorespiratory and autonomic risk factors

> “Notably, cardiorespiratory dysfunction may account for 26% to 47% of sudden, unexpected Rett syndrome-associated deaths.”

Source: [Tarquinio et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6026556/)

> “Following a review of the articles relating to sudden death, we identified reduced heart rate variability, epilepsy and deleterious changes in cardiac repolarization (QT prolongation and T-wave changes) as potential risk factors for sudden death.”

Source: [Singh et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7828978/)

<a id="topic-2.2.1.3-10"></a>

###### Risk factors for mortality: severity, ambulation, weight, seizures, and genotype

> “For classic RTT, several variables, such as ambulation, frequent seizures, frequent hospitalizations and illness, microcephaly and low weight, were independently associated with higher odds of mortality using a Cox proportional hazard model (Table 4).”
> “However, the majority of those who died (54%, or 19/35) weighed less than the 25th percentile on the Rett-specific charts, compared to 22% of those who survived (p < .001).”

Source: [Tarquinio et al. (2015b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4609589/)

> “Using the Cox proportional hazard model, those with large deletions had, at any time during the observation period, slightly more than 3 times (HR 3.11, 95% CI 0.60, 16.10) the risk of death than those with the p.Arg133Cys mutation.”

Source: [Anderson et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4078387/)

Additional sources: [ClinicalTrials.gov NCT00299312](https://clinicaltrials.gov/study/NCT00299312); [ClinicalTrials.gov NCT02738281](https://clinicaltrials.gov/study/NCT02738281)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### MeCP2 expression in the nervous system

> “MeCP2 is an abundant nuclear protein that was originally identified in a screen for proteins with methyl-DNA-specific binding activity. It is ubiquitously expressed throughout all human tissues, but is particularly abundant within neurons”
> “In the central nervous system (CNS), MeCP2 is expressed at low levels prenatally, but progressively increases during neuronal maturation and synaptogenesis reaching its peak in mature, post-migratory neurons, suggesting a role for MeCP2 in maintaining neuronal maturation, activity and plasticity”

Source: [Kyle et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5830535/)

> “MECP2 plays a particularly important role in synaptic development, neuronal maturation, and epigenetic regulation in the brain.”

Source: [Choi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12428351/)

<a id="topic-2.2.1.4-2"></a>

###### MeCP2 as a transcriptional regulator

> “These findings have led to a model wherein MeCP2 serves as a bridge between methylated DNA and the corepressor complex, anchoring the NCoR1/SMRT complex to DNA via its NID and MBD, respectively. It is hypothesized that disruption of this bridge leads to histone hyperacetylation and an open chromatin state, thereby increasing the transcription of target genes”

Source: [Kyle et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5830535/)

> “Scientists know that lack of a properly functioning MeCP2 protein disturbs the function of mature brain cells, but they do not know the exact mechanisms by which this happens.”

Source: [NINDS](https://www.ninds.nih.gov/health-information/disorders/rett-syndrome)

<a id="topic-2.2.1.4-3"></a>

###### Loss of function and location of pathogenic variants

> “It has been suggested that pathogenic variants result in loss of protein function; some functional studies show that pathogenic MECP2 variants affect the MBD or TRD domains of the abnormal protein, depending on the location of the variant”
> “The majority of pathogenic variants occur in the region encoding the methyl binding domain (MBD, exons 3 and 4; amino acids 90-174 of the MeCP2 e2 isoform), affecting the ability of the MeCP2 protein to bind to target DNA.”

Source: [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/)

> “eight common mutations (R106W, R133C, T158M, R168X, R255X, R270X, R294X, R306C) account for more than 60% of typical RTT individuals.”

Source: [Neul et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2677974/)

<a id="topic-2.2.1.4-4"></a>

###### Neuropathology: reduced brain and neuronal size without neuronal death

> “Studies employing neuroimaging, neuropathology, neurochemistry and animal models show reductions in brain size and global decreases in neuronal size, as well as alterations in multiple neurotransmitter systems.”

Source: [Gold et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39511247/)

> “Reduced brain volume is largely due to small neuronal body size and a denser packing of cells, particularly in layers III and V of the cerebral cortex, thalamus, substantia nigra, basal ganglia, amygdala, cerebellum and hippocampus”
> “Patients also have reduced dendritic arborization, indicative of a delay in neuronal maturation”

Source: [Kyle et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5830535/)

> “Neuronal death is absent suggesting that this is not a neurodegenerative disorder.”

Source: [Guy et al. (2007)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7610836/)

<a id="topic-2.2.1.4-5"></a>

###### Neuronal and glial cell types affected

> “Cortical GABAergic neurons exhibit approximately 50% higher MECP2 expression level than non-GABAergic neurons, suggesting that MECP2 deficiency has a more significant effect on GABAergic neurons than on other neurons”
> “MECP2 deficiency in GABAergic neurons leads to the loss of multiple functions such as social behavior, learning, memory, motor function, stereotyped behaviors, and sensorimotor gating.”

Source: [Choi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12428351/)

> “Moreover, deletion of MeCP2 from glial cells induces a RTT-like phenotype, and re-introducing MeCP2 to astrocytes of Mecp2 null mice using GFAP-Cre improves symptoms and restores dendritic morphology”

Source: [Kyle et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5830535/)

<a id="topic-2.2.1.4-6"></a>

###### X-chromosome inactivation and cellular mosaicism in females

> “Female heterozygous RTT patients are mosaic, allowing some cells to express the mutant MECP2, while the others express the wild-type allele. XCI can be skewed preferentially so the mutant X chromosome is more or less expressed than the wild type, resulting in either a relatively more severe or milder presentation of RTT, respectively”

Source: [Kyle et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5830535/)

> “Because the MECP2 gene is subject to X‐chromosome inactivation (XCI), factors including MECP2 genotypic variation, tissue differences in XCI, and skewing of XCI all likely contribute to the clinical severity of individuals with RTT.”
> “The average XCI ratio in probands was slightly increased compared to their unaffected mothers (73% vs. 69%, p = .0006). Among the duos with informative XCI data, the majority of individuals with classic RTT had their paternal allele preferentially inactivated (n = 180/220, 82%).”

Source: [Fang et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9034674/)

> “Although variation in XCI can explain some of the variance in severity of individuals with RTT (approximately 20%)”

Source: [Neul et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2677974/)

<a id="topic-2.2.1.4-7"></a>

###### MECP2 genotype and clinical severity

> “Participants with the R133C mutation are less severely affected than those with R168X or large DNA deletions (p<0.05). Likewise, individuals with the R168X mutation are more severely affected than those with R294X and late carboxy-terminal truncating mutations (p<0.05).”
> “Individuals with R168X are less likely to walk (p=0.008), retain hand use (p=0.002), or use words (p=0.001).”

Source: [Neul et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2677974/)

> “Using a database of 1052 participants assessed over 4940 unique visits, the largest cohort of both typical and atypical RTT patients studied to date, we examined the relationship between MECP2 mutation status and measures of growth, motor coordination, communicative abilities, respiratory function, autonomic symptoms, scoliosis, and seizures over time.”
> “In contrast, p.Arg106Trp, p.Arg168X, p.Arg255X, p.Arg270X, Splice Sites, Large Deletions, Insertions, and Deletions were significantly more severe.”
> “However, clinical severity continues to become progressively worse with advancing age regardless of initial severity.”

Source: [Cuddapah et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4403764/)

<a id="topic-2.2.1.4-8"></a>

###### Reversal of the phenotype after MeCP2 restoration in mice

> “Using a mouse model, we demonstrate robust phenotypic reversal, as activation of MeCP2 expression leads to striking loss of advanced neurological symptoms in both immature and mature adult animals.”
> “By contrast, five out of six symptomatic Stop/y,cre animals were rescued by TM treatment.”

Source: [Guy et al. (2007)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7610836/)

<a id="topic-2.2.1.4-9"></a>

###### MECP2 dosage sensitivity

> “Activation of Mecp2 in Stop/y,cre males at this stage (bracket TM-1, Fig. 2A), prior to symptom onset, revealed toxicity associated with abrupt Mecp2 reactivation as 9 out of 17 mice developed neurological symptoms and died soon after the daily TM injection series”
> “The toxic effects resembled those caused by over-expression of an Mecp2 transgene in mice”

Source: [Guy et al. (2007)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7610836/)

> “The intersection of MDS and RTT is best described as a ‘Goldilocks paradigm’”
> “in which too much of MeCP2 (MDS) and too little (RTT) will result in a severe disease state and highlights the importance of regulating this multi-functional protein and the difficult task of potential therapeutic strategies in maintaining a narrow range of MECP2 levels.”

Source: [Ta et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8939085/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Clinical diagnostic criteria: 2010 consensus criteria for typical and atypical Rett syndrome

| Criterion | Quoted criterion |
| --- | --- |
| Feature that should prompt consideration | “Consider diagnosis when postnatal deceleration of head growth observed.” |
| Required for typical RTT | “A period of regression followed by recovery or stabilization” |
| Required for typical RTT | “All main criteria and all exclusion criteria” |
| Required for typical RTT | “Supportive criteria are not required, although often present in typical RTT” |
| Required for atypical RTT | “At least 2 out of the 4 main criteria” |
| Required for atypical RTT | “5 out of 11 supportive criteria” |
| Main criterion 1 | “Partial or complete loss of acquired purposeful hand skills.” |
| Main criterion 2 | “Partial or complete loss of acquired spoken language” |
| Main criterion 3 | “Gait abnormalities: Impaired (dyspraxic) or absence of ability.” |
| Main criterion 4 | “Stereotypic hand movements such as hand wringing/squeezing, clapping/tapping, mouthing and washing/rubbing automatisms” |
| Exclusion criterion for typical RTT | “Brain injury secondary to trauma (peri- or postnatally), neurometabolic disease, or severe infection that causes neurological problems” |
| Exclusion criterion for typical RTT | “Grossly abnormal psychomotor development in first 6 months of life” |

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

> “We limited the necessary criteria to the presence of regression plus four main criteria that are absolutely required for the diagnosis of typical RTT.”
> “In these new criteria, history of regression and ALL of the necessary and exclusion criteria MUST be met to make the diagnosis of typical RTT, without exception.”
> “we state that for the diagnosis of atypical RTT an individual MUST have a period of regression followed by recovery or stabilization.”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

<a id="topic-2.2.1.5-2"></a>

###### Young children: provisional diagnosis before regression is evident

> “Because MECP2 mutations are now identified in some individuals prior to any clear evidence of regression, the diagnosis of”
> “RTT should be given to those individuals under 3 years old who have not lost any skills but otherwise have clinical features suggestive of RTT. These individuals should be reassessed every 6–12 months for evidence of regression. If regression manifests, the diagnosis should then be changed to definite RTT. However, if the child does not show any evidence of regression by 5 years, the diagnosis of RTT should be questioned.”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

<a id="topic-2.2.1.5-3"></a>

###### Validation of the criteria in the US Natural History Study: 819 participants

> “The present analysis was conducted on 819 participants enrolled as of February 28, 2010, to assess the recently modified clinical criteria.”
> “Of 765 females fulfilling criteria for classic or variant RTT, 653 (85.4%) were diagnosed as classic and 112 (14.6%) were classified as variant. A mutation was identified in 95% of 653 females with classic and 73.2% of 112 females with variant RTT”
> “Abnormal deceleration in the rate of head growth was noted in 82%”
> “For classic RTT, these core criteria are sufficient for diagnosis as none of the eight 2002 supportive criteria is noted uniformly. For variant RTT, diagnosis requires application of both main (2 of 4) and supportive (5 of 11) criteria.”

Source: [Percy et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3021984/)

<a id="topic-2.2.1.5-4"></a>

###### Genetic testing: MECP2 sequencing with deletion and duplication analysis

> “For suspicion of RTT, MECP2 gene sequencing and MLPA testing are recommended. MLPA testing is needed to detect deletions otherwise missed by sequencing; this test is necessary if no abnormalities are found by sequencing. Referral to a geneticist or genetic counsellor is recommended to review recurrence risks and answer related questions. Genetic testing results are essential for enrolment in clinical trials.”
> “Complete genetic testing involves sequencing and methods to detect larger deletions (eg, multiplex ligation-dependent probe amplification) of the MECP2 gene.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

> “Second, thorough and complete genetic testing for mutations in MECP2 should be performed on all participants. This would include sequencing of the coding region as well as methods such as MLPA, quantitative PCR, microarray methods, or Southern blotting to detect large DNA rearrangements.”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

<a id="topic-2.2.1.5-5"></a>

###### Genetic testing: diagnostic yield of next-generation sequencing in 1,577 patients with a Rett-like presentation

> “We studied 1577 patients with RTT-like clinical diagnoses and reviewed patients who were previously studied and thought to have RTT genes by Sanger sequencing. Genetically, 477 of 1577 patients with a RTT-like suspicion have been diagnosed. Positive results were found in 30% by Sanger sequencing, 23% with a custom panel, 24% with a commercial panel and 32% with whole exome sequencing.”

Source: [Vidal et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5613000/)

<a id="topic-2.2.1.5-6"></a>

###### Genetic testing: missed variant after repeated sequencing

> “Here, we describe a young woman with clinically diagnosed Typical RTT syndrome who lacked a genetic diagnosis despite 20 years of investigation and multiple rounds of sequencing the MECP2 gene.”
> “This case illustrates the evolving landscape of genetic testing technologies and the limitations of Next Generation (NextGen) sequencing due to deletions, duplications and insertions.”

Source: [Abbott et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11502282/)

<a id="topic-2.2.1.5-7"></a>

###### Age at diagnosis: US Natural History Study, 1,085 participants

> “Among 919 classic and 166 atypical RTT participants, median diagnosis age was 2.7 years (interquartile range 2.0–4.1) in classic and 3.8 years (interquartile range 2.3–6.9) in atypical RTT. Pediatricians made the diagnosis of classic RTT rarely (5.2%); however, proportion diagnosed by pediatricians increased since 2006.”
> “33% with microcephaly before 2.5 years were diagnosed after the median age of 2.7 years.”

Source: [Tarquinio et al. (2015a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4442062/)

<a id="topic-2.2.1.5-8"></a>

###### Age at diagnosis: international caregiver survey, 756 caregivers

> “The mean and median age of diagnosis were 4.3. and 2.8 years, respectively (classic RTT mean 3.8 years, median 2.5 years; atypical RTT mean 5.7 years, median 3.9 years)”

Source: [Kaufmann et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11323357/)

<a id="topic-2.2.1.5-9"></a>

###### Age at diagnosis: trends and predictors of delay in Australian and international registries

> “The median age of Rett syndrome diagnosis decreased from 4.5 years if diagnosed before 2000 to 3.5 years if diagnosed after 1999.”

Source: [Fehr et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3152673/)

> “A total of 909 cases were included. An older age of diagnosis was associated with later loss of hand function and speech, later onset of hand stereotypies and the presence of the p.R133C or p.R294X MECP2 mutation.”
> “Cases with a p.R133C mutation (adjusted mean 76.5 months) and those with a p.R294X mutation (adjusted mean 69.6 months) had a later age of diagnosis compared to those with a p.T158M mutation (adjusted mean 50.5 months).”

Source: [Fehr et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3906205/)

Additional sources: [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/); [McKnight et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9135956/); [Kim et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39255539/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Multisystem involvement: prevalence of comorbidities by organ system

> “Neurological comorbidities had the highest prevalence, occurring in nearly all individuals with gastrointestinal and orthopaedic concerns almost as prevalent as neurological. With the exception of low bone mineral content which was relatively common, endocrine comorbidities were seen in only around one-third of patients. Although more prevalent compared with the general population, cardiac conduction abnormalities were the least common comorbidity in RTT.”

Source: [Fu et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7509967/)

> “Of 6253 records screened, 148 studies met inclusion criteria, spanning 24 countries and participants aged 7 months to 37 years.”
> “Epilepsy prevalence ranged from 15.0% to 91.0%, scoliosis 8.9–100% and gastrointestinal dysfunction was common, including constipation (16.4–82.8%) and gastroesophageal reflux (15.8–100.0%).”

Source: [Rashid et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556918/)

<a id="topic-2.2.1.6-2"></a>

###### Motor symptoms: loss of purposeful hand use

> “Following the initial regression period, hand function continues to decline across the age spectrum in individuals with RTT.”

Source: [Neul et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10939125/)

> “Conversely, more than 70% of individuals had delays in ambulation (Table 2C) and nearly 100% had abnormalities in hand function (Table 2D), both in keeping with two of the four main diagnostic criteria for classic RTT.”

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)

<a id="topic-2.2.1.6-3"></a>

###### Motor symptoms: hand stereotypies

> “HS were reported in 922 participants with classic RTT (100%), 73 with atypical severe RTT (97.3%), 74 with atypical mild RTT (96.1%), and 17 females with MECP2 mutations without RTT (34.7%).”
> “While hand function decreased over time, prevalence and frequency of HS remained relatively unchanged and high.”

Source: [Stallworth et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6556084/)

> “Hand stereotypies were reported in 11.4% of studies, with prevalence of 70.0–100.0%.”

Source: [Rashid et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556918/)

<a id="topic-2.2.1.6-4"></a>

###### Motor symptoms: gait impairment and loss of ambulation

> “More than 31% had delayed acquisition, and 8% had lost the previously acquired ambulation skill. In addition, nearly 34% had never acquired the ability to ambulate.”

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)

> “Ambulation varies significantly among RTT patients, with prevalence ranging from 12.0% to 73.0% across eight different studies.”

Source: [Rashid et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556918/)

<a id="topic-2.2.1.6-5"></a>

###### Motor symptoms: dystonia, rigidity, and other movement abnormalities

> “Outside of the repetitive hand movements that are part of the main diagnostic criteria of typical RTT, additional movement abnormalities are found in 60%–80% involving varying combinations of dystonia, tremor, myoclonus, chorea and progressive limb rigidity with bradykinesia resembling parkinsonism.”

Source: [Fu et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7509967/)

> “Six studies reported on the prevalence of dystonia ranging from 18.2% to 95.5%”

Source: [Rashid et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556918/)

<a id="topic-2.2.1.6-6"></a>

###### Communication symptoms: loss of spoken language and impaired nonverbal communication

> “Nearly all participants had delays in language development (Table 2F) and 90% had abnormalities in nonverbal communication (Table 2G), again reflecting significant difficulties in one of the main diagnostic features for classic RTT.”

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)

> “The percentage of participants who lost previously gained skills ranged from 6.6% (Lift Head) to 88.6% (Words with Meaning).”
> “Similarly, within expressive language, nearly all participants gained early skills such as Cooing and Babbling, but less than 25% gained Spoken Phrases.”

Source: [Neul et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094048/)

<a id="topic-2.2.1.6-7"></a>

###### Cognitive symptoms: intellectual disability

> “Intellectual disability is prevalent in 68.0–100.0% of patients according to different studies, while microcephaly is common, with prevalence ranging from 19.0% to 100.0% across ten studies.”

Source: [Rashid et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556918/)

<a id="topic-2.2.1.6-8"></a>

###### Neurological symptoms: epilepsy

> “While point prevalence of active seizures ranged from 30% to 44%, the estimated cumulative lifetime prevalence of epilepsy using Kaplan-Meier approached 90%.”

Source: [Tarquinio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5278305/)

> “A total of 360 (60%) were reported to have seizures, including 315 (60%) classic and 45 (61%) atypical RTT. Physician assessment of the 602 indicated that 48% had seizures.”
> “A significant age impact for seizures was seen and seizures were infrequent before age 2 years.”

Source: [Glaze et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2836870/)

<a id="topic-2.2.1.6-9"></a>

###### Autonomic symptoms: awake breathing abnormalities

> “Participants with classic or atypical severe RTT were more likely to have breathing dysfunction (nearly 100% over the lifespan) compared to those with atypical mild RTT (60-70%). Remission was common, lasting 1 year on average, with 15% ending the study in terminal remission.”

Source: [Tarquinio et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6026556/)

> “In terms of respiratory function (Table 2H), nearly 50% presented evidence of significant breath‐holding or hyperventilation (or both), and more than 25% had some degree of abnormality.”

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)

<a id="topic-2.2.1.6-10"></a>

###### Autonomic symptoms: cold hands and feet

> “About 60% had abnormal autonomic function (Table 2I) with cool or cold hands and/or feet.”

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)

<a id="topic-2.2.1.6-11"></a>

###### Cardiac signs: QTc prolongation

> “Of the 613 participants with classic and atypical RTT who had EKG data, 18% had a borderline and 10% had an abnormal QTc interval.”

Source: [Tarquinio et al. (2015b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4609589/)

> “Mean QTc of the cohort was 422.6 msec, which did not exceed the normal values for age. 7/100 patients (7%) had QTc prolongation (>450 msec).”

Source: [Crosson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5444992/)

> “Finally, cardiac conduction abnormalities involving prolonged QT interval are seen in 10%–18%.”

Source: [Fu et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7509967/)

<a id="topic-2.2.1.6-12"></a>

###### Gastrointestinal symptoms: constipation, reflux, and biliary disease

> “In addition to the highly prevalent neurodevelopmental issues, gastrointestinal and orthopaedic comorbidities are both also quite prevalent, each reported in over 80% of individuals.”
> “The gastrointestinal issues primarily involve constipation but around 40% also have gastro-oesophageal reflux.”

Source: [Fu et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7509967/)

> “GI manifestations affected 43.0% of 5940 patients, with increased prevalence in pediatric patients (45.6%) relative to adult patients (40.2%).”
> “Importantly, the prevalence of GI manifestations was likely underestimated in this study, as only those symptoms which resulted in a healthcare encounter were captured.”

Source: [May et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10842289/)

<a id="topic-2.2.1.6-13"></a>

###### Oral and feeding symptoms: swallowing dysfunction and drooling

> “Impaired swallowing function has equal prevalence to epilepsy over the lifespan but becomes apparent at a younger age often manifesting in early childhood as prolonged feeding times, choking/gagging on food and/or aspiration of liquids.”

Source: [Fu et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7509967/)

> “Among eight studies which reported on dysphagia and chewing problems, the prevalence ranged from 23.5% to 76.7%”
> “Drooling was also reported in five studies ranging from 39.2% to 92.9% among the patients”

Source: [Rashid et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556918/)

<a id="topic-2.2.1.6-14"></a>

###### Growth: deceleration of head growth and somatic growth failure

> “Mean growth in classic RTT decreased below that for the normative population at 1 month for head circumference, 6 months for weight, and 17 months for length. Mean BMI was similar in those with RTT and the normative population. Pubertal increases in height and weight were absent in classic RTT.”

Source: [Tarquinio et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3468773/)

> “Head growth (Table 1C) was normal in 27.6% and microcephalic by age 2 years in 28.6%.”

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)

<a id="topic-2.2.1.6-15"></a>

###### Endocrine signs: altered pubertal timing

> “The timing of secondary sexual characteristics is also frequently altered in RTT with early adrenarche or thelarche in a quarter and just under 20% with delayed menarche.”

Source: [Fu et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7509967/)

<a id="topic-2.2.1.6-16"></a>

###### Sleep symptoms: sleep disturbance and sleep-disordered breathing

> “Sleep problems were identified in over 80% of cases. The prevalence of night-time laughter decreased with age and the prevalence of reported night-time seizures and daytime napping increased with age.”

Source: [Young et al. (2007)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2527512/)

> “Six of thirteen participants had obstructive sleep apnea, which was worse during rapid eye movement (REM) sleep with associated hypoxemia and disruptions in sleep architecture.”

Source: [Peters et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12354067/)

<a id="topic-2.2.1.6-17"></a>

###### Behavioral symptoms: anxiety and internalizing behavior

> “Most participants with RTT (77.5%) had at least occasional anxious or nervous behavior.”

Source: [Buchanan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9107202/)

> “Behaviour disturbances occur in nearly all individuals with RTT across the lifespan with internalising behaviours such as anxiety or mood swings being much more common overall than externalising behaviours such as aggression, hyperactivity or self-injury which are seen in about 40% of individuals, almost always with onset before 3 years of age and which improve over time in contrast to the internalising behaviours.”

Source: [Fu et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7509967/)

<a id="topic-2.2.1.6-18"></a>

###### Pain: frequency, sources, and expression

> “Of the 44 families responding to the survey, 24% reported that their child had experienced pain on 8 or more days (> 1 week) in the previous 30 days (43% were unsure)”
> “Ninety percent of the individuals reported on with RTT did not use words for pain. The most frequent form of pain communication was facial expression (85%) and vocalization (82%, e.g., moan, cry).”
> “The most commonly reported pain source was gastrointestinal [GI] (66%)”

Source: [Symons et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3707000/)

<a id="topic-2.2.1.6-19"></a>

###### Orthopaedic signs: scoliosis, hip displacement, and foot deformities

> “This meta-analysis found that approximately two in three girls with RTT develop scoliosis, one in two exhibit foot deformities and one in three experience hip displacement.”

Source: [Galán-Olleros et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39429113/)

> “Although scoliosis (Table 2E) was absent in greater than 50%, the appearance of abnormal curvature in nearly 35% as well as the evidence of surgical correction in 11.8% indicated nearly half having significant difficulties with spinal deformity.”

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Health status in adulthood: mobility, scoliosis, epilepsy, and gastrointestinal problems

> “The median age of the combined cross-sectional cohort was 25 years (range 18 to 54 years), the majority (71%) were living in their parental home and the remainder being cared for in group homes or other institutions. Just over half walked either independently (18%) or with assistance (43%). The majority (86%) had scoliosis with 40% of those having undergone corrective surgery. Almost two-thirds (64%) of the women were taking anti-epileptic medications at the time of data collection. Constipation was highly prevalent (83%) and many experienced bloating (53%).”
> “Sleep disturbance was relatively common (63%), and adverse mood events and anxiety were slightly more prevalent in those aged 26-30 years in comparison to the younger and older age groups. Other frequently reported medical conditions included urinary tract infections, pneumonia and other respiratory conditions.”

Source: [Anderson et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4078387/)

<a id="topic-2.2.1.7-2"></a>

###### Scoliosis: progression to severe curves and spinal surgery

> “913 females with classic RTT were included. Scoliosis frequency and severity increased with age. Severe scoliosis was found in 251 participants (27%), 113 of whom developed severe scoliosis during the follow-up assessments. 168 (18%) had surgical correction.”
> “In terms of the actual age distribution for the 168 participants who had surgical correction, the majority (86%) occurred between age 9 and 15, the median age was 12 years (min=5, max=21).”

Source: [Killian et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5461984/)

> “All 30 women had scoliosis that progressed slowly throughout their lives, but only one was reported as having undergone surgery.”

Source: [Hryniewiecka-Jaworska et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11975466/)

<a id="topic-2.2.1.7-3"></a>

###### Gross motor decline in adolescence and adulthood

> “here we demonstrate that slow loss of gross motor skills occurs during Stage III.”

Source: [Neul et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094048/)

> “The study included 24 individuals aged 30-66 years at last visit after a follow-up period of 6-12 years. Results showed a clinically observable and significant decline in gross motor skills using the Rett syndrome Gross Motor Scale (RSGMS) with a tendency of less decline in the individuals with the best motor abilities.”
> “Decline in RSGMS score was associated with the presence of epilepsy and severe scoliosis that had been conservatively managed.”

Source: [Bisgaard et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34296518/)

> “Of those 26 women walking after their childhood regression, two (8%) permanently lost their ability to walk in their 20s and nine (37.5%) of those still walking in their 40s lost that ability during their 40s or 50s.”

Source: [Hryniewiecka-Jaworska et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11975466/)

<a id="topic-2.2.1.7-4"></a>

###### Bone health: low bone mass and fractures

> “however individuals as young as three and four years of age had low BMC and aBMD values in the lumbar spine”
> “The fracture incidence in an Australian RTT population was shown to be 43.3 per 1000 person years, which equates to a rate nearly four times that of the general population”

Source: [Jefferson et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4743907/)

<a id="topic-2.2.1.7-5"></a>

###### Respiratory complications: aspiration, lower respiratory tract infection, and respiratory failure

> “Of the 1,994 with RTT, 7.27% (n = 145), 9.48% (n = 189), and 10.08% (n = 201) experienced post-index aspiration, LRTI, and RF, respectively.”

Source: [Rajagopalan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12580911/)

> “Of eligible individuals, 25 (28.1%) were aspiration cases. The cumulative rate of RF among RTT individuals with and without aspiration was 60.0% and 6.3%, respectively.”
> “Aspiration cases were more likely to have LRTI (50% vs. 5.0%) and ≥ 1 inpatient admissions than non-aspiration controls (75.0% vs. 35.0%) (all p < 0.05).”

Source: [Rashid et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12082938/)

<a id="topic-2.2.1.7-6"></a>

###### Epilepsy: course across the lifespan

> “Three distinct patterns of seizure prevalence emerged in classic Rett syndrome, including those who did not have seizures throughout the study, those who had frequent relapse and remission, and those who had relentless seizures. Although 248 of those with classic Rett syndrome and a history of seizures were in terminal remission at last contact, only 74 (12% of those with a history of epilepsy) were seizure free and off anti-seizure medication.”

Source: [Tarquinio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5278305/)

> “Seizures were reported for 18 of 30 women (60%) at some stage during their lives. Ten (33%) had epileptic seizures in middle age, usually generalised tonic–clonic (GTC) or myoclonic seizures, with the seizures being well controlled on medication in nine.”

Source: [Hryniewiecka-Jaworska et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11975466/)

<a id="topic-2.2.1.7-7"></a>

###### Mood in middle age: unexplained sadness

> “Twenty‐five women (83%) had episodes of unexplained sadness at some point in their lives. Nine women (30%) had unexplained weight loss during adulthood.”

Source: [Hryniewiecka-Jaworska et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11975466/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Rett syndrome

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Child health-related quality of life: CHQ-PF50 in the US Natural History Study

> “More than 200 participants from 5 to 18 years of age with classic RTT finished their 2-year follow-up at the time of analysis.”
> “Each CHQ-PF50 domain score was compared with the standard US girl score reported in the QOL manual. All scores other than those for Behavior and Family Cohesion were significantly lower than those from standard US girls.”
> “Severe clinical impairment was highly associated with poor physical QOL, but worse motor function and earlier age at onset of RTT stereotypies were associated with better psychosocial QOL; conversely, better motor function was associated with poorer psychosocial QOL.”

Source: [Lane et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3233210/)

<a id="topic-2.2.1.8.1-2"></a>

###### Child quality of life and family functioning: PedsQL in 23 families in Poland

> “We included 23 parents of children with RTT. In this study, we used the PedsQL™ Family Impact Module, the Pediatric Quality of Life Inventory 4.0 generic core scales (PedsQL™ 4.0), and an author-designed questionnaire to assess QoL and family functioning.”
> “QOL in children with RTT, as perceived by their parents, is reduced. RTT has a significant negative correlation with family functioning.”

Source: [Rozensztrauch et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8111277/)

<a id="topic-2.2.1.8.1-3"></a>

###### Caregiver health-related quality of life: SF-36v2 in the US Natural History Study

> “Caretaker physical component scores (PCS) were higher than mental component scores (MCS): 52.8 (9.7) versus 44.5 (12.1). No differences were noted between the baseline and 5-year follow-up. In univariate analyses, disease severity was associated with poorer PCS (p=0.006) and improved MCS (p=0.003). Feeding problems were associated with poorer PCS (p=0.007) and poorer MCS (p=0.018).”
> “The PCS and MCS scores of 35-44 year old females from the United States general population are 51.6 (8.6) and 47.8 (10.4) respectively”
> “For caretakers of those with RTT, this demonstrates similarity of PCS to the general population, but lower MCS scores at 44.6 (12.1).”

Source: [Killian et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4899118/)

<a id="topic-2.2.1.8.1-4"></a>

###### Caregiver health utility: EQ-5D-5L and CarerQol-7D in 37 UK caregivers

> “A multi-method study was conducted between June-August 2025 with N=37 caregivers of individuals with RTT in the UK.”
> “The mean EQ-5D-5L score of caregivers was 0.62 (SD=0.25), with 49% and 38% reporting moderate-to-severe problems with anxiety/depression and pain/discomfort, respectively. Mean CarerQoL-7D utility was 60.76 (SD=18.11) with impacts on daily activities and finances being most reported.”
> “Worsening physical health (95%) due to ongoing fatigue, sleep disturbance, and the physical demands of caregiving were also commonly reported. All participants also described experiencing negative psychological impacts such as anxiety, depression and a sense of grief for the life they once envisioned for themselves and their child.”

Source: [Pimprikar et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-2-4/the-impact-of-caring-for-their-children-with-rett-syndrome-a-multi-method-study)

<a id="topic-2.2.1.8.1-5"></a>

###### Parenting stress: Parenting Stress Index in 35 caregivers

> “A majority (60%) of parents reported stress in the clinical range on at least one subscale of the Parenting Stress Index – Short Form. Seizures and uncertainty about their daughter’s gastrointestinal pain experience were significantly associated with higher levels of parenting stress.”

Source: [Byiers et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3992319/)

<a id="topic-2.2.1.8.1-6"></a>

###### Burden of illness: disorder-specific caregiver survey of 756 caregivers in the USA, Europe, and Australia

> “The questionnaire was administered anonymously online to an international sample of 756 caregivers (predominantly parents) of girls and women with RTT.”
> “There was variability in reported frequency of problems, with the most prevalent, severe and impactful being those related to the core features of RTT (i.e., communication and fine and gross motor impairments).”
> “ANOVAs showed that many problems had disproportionately greater impact than severity, either on affected individuals (e.g., hand stereotypies) or their caregivers (e.g., sleep difficulties, seizures, pain, and behavioral abnormalities).”
> “There was a wide range of frequency of problems, from ~ 35% for hyperventilation to 99% for impairments in self-care activities of daily living. Core features or impairments were present in 70–98% of affected individuals, while other problems were more variable.”

Source: [Kaufmann et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11323357/)

<a id="topic-2.2.1.8.1-7"></a>

###### Caregiver priorities: top concerns in the US Natural History Study, 925 caregivers

> “Caregivers of participants enrolled in the US Natural History Study of RTT and RTT-related disorders (n = 925) were asked to identify the top 3 concerning problems impacting the affected participant.”
> “The top caregiver concerns for classic RTT were effective communication, seizures, walking/balance issues, lack of hand use, and constipation.”

Source: [Neul et al. (2023c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10571464/)

<a id="topic-2.2.1.8.1-8"></a>

###### Symptoms with severe impact on quality of life: TSHA-102 sponsor caregiver survey, 323 caregivers in four countries

> “This work was funded by Taysha Gene Therapies, Inc., in accordance with Good Publications Practice.”
> “In total, 323 caregivers from the USA (n = 85), the UK (n = 115), Canada (n = 45), and Israel (n = 78) participated.”
> “Symptoms that were most commonly reported as having a severe impact on quality of life (QoL) included loss of speech (81%, n = 261), loss of purposeful hand use (80%, n = 259), loss of independent walking (61%, n = 198), loss of mobility (59%, n = 189), and involuntary hand movements (57%, n = 184).”
> “Over three-quarters of respondents (76%, n = 245) indicated that ≥ 1 new or newly challenging symptom had emerged in the 2 years prior to the survey, the most common of which was the loss of mobility, reported by 63% of caregivers.”

Source: [Ben-Zeev et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13615242/)

<a id="topic-2.2.1.8.1-9"></a>

###### Impact on daily activities: caregiver diaries in eight European countries

> “Sixty caregivers across eight countries completed five-day diaries, and thirty participated in in-depth interviews.”
> “Daily activities were heavily affected, with symptoms impacting 59% of activities for children, 61% for adolescents, and 38% for adults.”

Source: [Pulles et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13721293/)

<a id="topic-2.2.1.8.1-10"></a>

###### Care coordination and caregiver stress: parent survey in Italy

> “The data refers to 52 patients, all females, with a median age of 15 years at the time of the survey.”
> “The study shows that caregivers of RS patients take over most obligations and burdens by increasing their perceived level of stress. For the majority of patients, the most frequent complications were not followed by the reference subspecialist, with the only exception of epilepsy.”

Source: [Cherchi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10605630/)

<a id="topic-2.2.1.8.1-11"></a>

###### Patient health utility: utility weights derived from the Rett Syndrome Behaviour Questionnaire

> “This study was conducted to develop utility-based scoring weights from the 45-item Rett Syndrome Behaviour Questionnaire (RSBQ), a disease-specific measure.”
> “Disutility weights for each level of each attribute were calculated using the DCE model coefficients rescaled against the worst and best health states, which ranged from 0.22 to 0.87.”

Source: [Skrobanski et al. (2025)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2025/poster-session-5-2/the-estimation-of-utility-weights-from-the-rett-syndrome-behavior-questionnaire)

Additional sources: [Epstein et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26686505/); [Strugnell et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31074665/); [Downs et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30460513/); [Corchón et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30220073/); [McGraw et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37161302/); [Wong et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29941161/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### US claims, 5,940 females: all-cause and Rett-related healthcare resource utilization

> “Among 5,940 female patients (pediatric: 3,078; adult: 2,862) with mean observation period of 2.04 years, the most prevalent clinical manifestations were neurological disorders (72.8%), gastrointestinal/nutritional disorders (41.9%), and orthopedic disorders (34.6%).”
> “The incidence rate of all-cause HRU by place of service among female patients with RTT was 44.43 visits PPPY during the observation period, primarily driven by home/hospice care (16.31 visits PPPY), OP visits (9.58 visits PPPY), and therapeutic service visits (7.26 visits PPPY; Table 6).”
> “All-cause HRU largely comprised of RTT-related HRU, with 47% of the all-cause incidence rate attributed to a RTT diagnosis in the overall study population (Table 6).”
> “Trends were similar by subgroup; although, rates of HRU were generally higher among pediatric patients relative to adult patients (all-cause: 52.43 and 35.86, respectively), which translated into higher mean healthcare costs (all-cause: $45,718 and $34,548, respectively).”

Source: [May et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10071755/)

<a id="topic-2.2.1.8.2-2"></a>

###### US claims, 5,940 females: all-cause and Rett-related healthcare costs

> “Mean all-cause healthcare costs were $40,326 per-patient-per-year, with medical costs driven by home/hospice care visits, therapeutic services, outpatient visits, and inpatient visits.”
> “RTT-related healthcare costs comprised 45% of all-cause healthcare costs.”
> “During the observation period, female patients with RTT incurred mean all-cause total healthcare costs of $34,772 (86%) in pre-adjudicated medical costs and $5,554 (14%) in adjudicated pharmacy costs (Table 7).”
> “Mean all-cause medical costs were primarily driven by home/hospice care visits ($12,054), followed by therapeutic services ($7,071), OP visits ($6,791), and inpatient visits ($6,088) among the overall cohort.”
> “Mean RTT-related total healthcare costs PPPY included $14,643 in pre-adjudicated medical costs and $3,428 in adjudicated pharmacy costs (Table 7).”
> “All costs were inflation-adjusted to 2021 US dollars (USD).”

Source: [May et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10071755/)

<a id="topic-2.2.1.8.2-3"></a>

###### US claims, 5,940 females: data source and cost limitations

> “Administrative healthcare claims data from the IQVIA™ Medical Claims Data (Dx) and Longitudinal Prescription Data (LRx) databases (11/1/2016–10/31/2019) were used to address the study objectives.”
> “This analysis relied on pre-adjudicated medical claims from IQVIA Dx database, for which payment amounts have not yet been finalized and are often inflated compared to their adjudicated equivalent. Therefore, healthcare costs may be overestimated.”
> “For example, overall coverage of institutional claims is lower than that of OP claims in the IQVIA Dx database, potentially resulting in incomplete capture of inpatient, ED, and long-term care/skilled nursing facility visits.”

Source: [May et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10071755/)

<a id="topic-2.2.1.8.2-4"></a>

###### US claims, 5,940 patients: cost of gastrointestinal manifestations

> “Mean medical costs of managing GI manifestations amounted to $4473 per patient per year (PPPY) and were somewhat higher in pediatric ($5530 PPPY) than adult ($3341 PPPY) patients.”
> “GERD was associated with the highest mean medical cost ($2630 PPPY), of which the largest component was the cost of therapeutic services (including physical therapy, hydrotherapy, occupational therapy, speech therapy, and feeding assistance), which amounted to $1071 PPPY (SD: $8264).”
> “The second most costly manifestation to manage was constipation ($923 PPPY), which mean cost PPPY was higher in pediatric than adult patients ($1010 vs $830, respectively).”
> “Mean medical costs were reported per patient per year (PPPY) to account for varying lengths of follow-up and inflation-adjusted to 2021 US dollars.”

Source: [May et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10842289/)

<a id="topic-2.2.1.8.2-5"></a>

###### Australian population: health sector costs converted to US dollars

> “While we have identified no studies reporting specifically on the costs of managing GI manifestations in RTT, in an analysis of the Australian Rett Syndrome Database, mean healthcare costs associated with RTT management overall were estimated at AUD 21,158 PPPY (equivalent to USD 25,691 as of December 2022 [14,15]), and ranged from AUD 238 to AUD 85,776 (equivalent to USD 289 to USD 104,151 [14,15]) [16], also suggesting substantial between-patient variability in the healthcare costs incurred.”

Source: [May et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10842289/)

<a id="topic-2.2.1.8.2-6"></a>

###### US Natural History Study registry, 455 females: hospital and emergency room visits and gastrostomy

> “Over a median follow-up period of 4 years, nearly half (44.6%) of all individuals had a hospital or emergency room visit (Fig. 2), with a significantly higher proportion of visits observed in individuals with classic RTT than atypical RTT (47.1% vs. 20.9%, p = 0.001), and pediatric individuals than adult individuals (48.5% vs. 29.3%, p = 0.001) (Supplementary Table 2).”
> “Incident g-tube surgeries were observed among 13.7% of individuals, and pediatric individuals had a significantly higher incidence of g-tube surgery than adult individuals (16.7% vs. 2.7%, p = 0.002) (Supplementary Table 2).”

Source: [May et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11282812/)

<a id="topic-2.2.1.8.2-7"></a>

###### Ontario, Canada, population data: healthcare touchpoints

> “In total, 246 RTT cases were indexed; 40% from central Ontario, 95% female, median age 21 years.”
> “Most patients had at least one outpatient visit (primary care 96.7%, specialist 86.6%), emergency department visit (76.8%) and inpatient hospitalization (54.5%).”
> “During the 5-year follow-up period, most cases (95.1%) had at least one public claim for all-cause medication.”

Source: [Bond et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41267498/)

<a id="topic-2.2.1.8.2-8"></a>

###### Epilepsy: emergency department visits and inpatient admissions at a US Rett center

> “In this analysis, 98 individuals with RTT were included: 71 (72%) had epilepsy of which 33 (46%) had severe epilepsy.”
> “Comparing all-cause HCRU during the 12-month follow up period (Figure 3), the prevalence of ED visits was significantly higher among those with severe epilepsy vs. those with non-severe epilepsy (27% vs. 7%, p < 0.05). Inpatient admissions were also significantly more prevalent among those with severe epilepsy vs. non-severe epilepsy (37% vs. 14%, p < 0.05).”
> “In the year following diagnosis, epilepsy-specific inpatient admissions were documented for 12 (20%) and ED visits for 4 (7%) of the 59 individuals with epilepsy (Figure 4).”

Source: [Rashid et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12549289/)

<a id="topic-2.2.1.8.2-9"></a>

###### Aspiration: inpatient admissions at a US Rett center

> “Of eligible individuals, 25 (28.1%) were aspiration cases.”
> “Aspiration cases were also significantly twice more likely to have ≥ 1 inpatient admissions for any reason than non-aspiration controls (75.0% vs. 35.0%, p < 0.05). Rates of all-cause outpatient visits and ED visits were similar among the two groups; however, the number of inpatient admissions were higher for the aspiration cases vs. non-aspirating controls (9.4 vs. 2.6, ns), (Table 2).”

Source: [Rashid et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12082938/)

<a id="topic-2.2.1.8.2-10"></a>

###### Respiratory infection: hospital admissions in an international registry

> “A hospital admission for LRTI over the previous 5 years was reported for slightly more than one-fifth (21.4%) of individuals.”
> “Compared with independent walking, being unable to walk was associated with a sixfold increased risk (adjusted relative risk 6.73, 95% CI 3.42-13.25), with assisted walking associated with an intermediate risk.”

Source: [MacKay et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29536504/)

<a id="topic-2.2.1.8.2-11"></a>

###### Scoliosis surgery: inpatient length of stay and complications in the Kids' Inpatient Database

> “Using the International Classification of Diseases Ninth and 10th revision codes in the national Kids' Inpatient Database, we identified children with RTT who underwent PSF from 2000 to 2019.”
> “RTT diagnosis independently predicted higher odds of any complications (odds ratio: 1.98, P < 0.001) and increased length of stay (odds ratio: 1.18, P = 0.009) for admissions for PSF.”
> “The higher Elixhauser Comorbidity Index in RAS patients predicted higher costs, longer hospital stays, more complications (particularly respiratory), and more nonroutine discharge disposition than in other patients with NMS.”

Source: [Stone et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37642479/)

<a id="topic-2.2.1.8.2-12"></a>

###### Scoliosis surgery: length of stay, readmissions, and reoperations at one US center

> “The median estimated blood loss was 600 mL and length of stay was 7 days.”
> “There were 3 readmissions (12%) within 30 days for pneumonia and 2 (8%) reoperations (an incision and drainage and C2-T2 fusion for significant kyphosis) within 90 days.”

Source: [Taylor et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36882895/)

<a id="topic-2.2.1.8.2-13"></a>

###### Systematic literature review: cost and resource use evidence

> “Data were extracted from relevant publications reporting on clinical (n=40), humanistic (n=32), and cost/HCRU (n=11) outcomes (Figure 1).”
> “Limited cost data were available in the literature, but where comparative data were reported, healthcare costs associated with Rett syndrome were higher than healthcare costs for the general population. Residential care, home/hospice care visits, therapeutic services, and outpatient and inpatient visits were the main cost drivers.”
> “Furthermore, the absence of pharmacoeconomic models and comprehensive estimates of the total economic burden is noteworthy.”

Source: [May et al. (2024b)](https://acadia.com/en-us/pdf/healthcare-professionals/scientific-publications/congress-materials/2024_EAN_May_HTA_SLR_Pos.pdf)

Additional sources: [Hendrie et al. (2011)](https://doi.org/10.1016/j.rasd.2010.10.004); [Lotan (2019)](https://pubmed.ncbi.nlm.nih.gov/30644545/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Rett syndrome on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Caregiver employment and caregiving time: 37 UK caregivers

> “Average weekly time spent on caregiving tasks was 98.9 hours.”
> “Impacts of caregiving were described as sudden and life changing, including: restrictions to work (92%), social (92%) and daily (97%) activities which in turn contributed to strains in interpersonal relationships and finances. Only 14% of caregivers reported working full-time and 60% had stopped completely.”

Source: [Pimprikar et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-2-4/the-impact-of-caring-for-their-children-with-rett-syndrome-a-multi-method-study)

<a id="topic-2.2.1.8.3-2"></a>

###### Caregiving time by activity: caregiver diaries in eight European countries

> “Care demands were substantial, with caregivers of adults spending an average of 41 hours per week providing emotional support alone, along with high time requirements for feeding (20 hours), washing and bathing (8 hours), and administering medication (5 hours).”
> “Time spent on many caregiving activities was highest in adults, including washing and bathing (7.8 hours per week), feeding (20.3 hours per week), administering medication (5.4 hours per week), helping with physio exercises (5.2 hours per week), and managing the equipment of the patient (4.8 hours per week)”

Source: [Pulles et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13721293/)

<a id="topic-2.2.1.8.3-3"></a>

###### Lost employment and out-of-pocket expenses: Canadian patient group input to the trofinetide review

> “The groups noted that Rett syndrome can be overwhelming, and patients may require constant care, impacting caregivers and families emotionally, physically, and financially. Caregivers may need to reduce or leave employment to provide full-time care, while also facing increased expenses related to medical care, therapies, specialized equipment, home modifications, and travel to specialized centres.”
> “Many caregivers have reported reducing work hours or leaving employment entirely to provide care, exacerbating financial strain.”

Source: [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1)

<a id="topic-2.2.1.8.3-4"></a>

###### Family strain: TSHA-102 sponsor caregiver survey, 323 caregivers in four countries

> “Additionally, caregivers noted the impact of RTT symptoms on themselves (73%, n = 237) and other family members (33%, n = 105), as well as stress and strain on the family overall (52%, n = 167).”
> “Including financial strain, family dynamics, logistics of care, etc.”

Source: [Ben-Zeev et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13615242/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Procedure codes for MECP2 testing

> “81302: MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; full sequence analysis”
> “81303: MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; known familial variant”
> “81304: MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; duplication/deletion variants”

Source: [Blue Shield of California (2023)](https://blueshieldca.com/content/dam/bsca/en/provider/docs/medical-policies/Genetic-Test-Rett-Syndrome.pdf)

<a id="topic-2.2.1.8.4-2"></a>

###### US payer coverage criteria: medical necessity of genetic testing

> “Genetic testing for Rett syndrome−associated genes (e.g., MECP2, FOXG1, or CDKL5) may be considered medically necessary to establish a genetic diagnosis of Rett syndrome in a child with developmental delay and signs/symptoms of Rett syndrome, when a definitive diagnosis cannot be made without genetic testing.”
> “Targeted genetic testing for a known familial Rett syndrome−associated variant may be considered medically necessary to determine carrier status of a mother or a sister of an individual with Rett syndrome.”
> “There are no studies that report direct evidence on the clinical utility of genetic testing for RTT.”

Source: [Blue Shield of California (2023)](https://blueshieldca.com/content/dam/bsca/en/provider/docs/medical-policies/Genetic-Test-Rett-Syndrome.pdf)

<a id="topic-2.2.1.8.4-3"></a>

###### US laboratory list prices: pediatric hospital molecular diagnostics laboratory, 2026

| Test | CPT code | 2026 price | CPT code, known familial variant | 2026 price, known familial variant |
| --- | --- | --- | --- | --- |
| MECP2 sequencing | “81302” | “$685” | “81303” | “$225” |
| MECP2 deletion/duplication | “81304” | “$300” | “81303” | “$300” |

Source: [Nemours (2026)](https://www.nemours.org/content/dam/nemours/nemours-org/en/documents/molecular-diagnostic-lab-cpt-codes-and-billing.pdf)

<a id="topic-2.2.1.8.4-4"></a>

###### US laboratory list prices: MECP2 Sanger sequencing at a genetics center

| Field | Quoted record |
| --- | --- |
| Turnaround time | “21 days” |
| Price | “$900” |
| CPT code | “81302” |
| Method | “This test is performed by Sanger sequencing.” |
| Ordering of deletion/duplication analysis | “Sequencing of the MECP2 gene and MLPA deletion/duplication analysis can be ordered concurrently, sequentially or separately.” |

Source: [Greenwood Genetic Center](https://ggc.org/tests/rett-syndrome-mecp2-sequencing/)

<a id="topic-2.2.1.8.4-5"></a>

###### Next-generation sequencing: effect on turnaround and cost

> “A genetic study using NGS allows the study of a larger number of genes associated with RTT-like symptoms simultaneously, providing genetic study of a wider group of patients as well as significantly reducing the response time and cost of the study.”

Source: [Vidal et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5613000/)

<a id="topic-2.2.1.8.4-6"></a>

###### Canadian testing costs, turnaround, and out-of-pocket costs: trofinetide reimbursement review

> “The total cost of MECP2 testing is approximately $1,307.45 per sample, which includes:”
> “$1,172.42 for Sanger sequencing and MLPA (i.e., $586.21 for each test processed in Alberta)”
> “The anticipated cost of ordering an MECP2 sequence and CNV detection test using NGS is US$990;”
> “according to a molecular testing inventory scan, the turnaround time in Alberta varies from 1 week to 2 weeks for urgent testing and from 6 weeks to 8 weeks for routine testing with both Sanger sequencing and MLPA.”
> “From the targeted jurisdictional survey, British Columbia indicated that in cases of MECP2 testing not approved for provincial reimbursement, out-of-pocket costs may be incurred by patients and their families.”
> “Repeat testing is not required once the MECP2 mutation status is confirmed.”
> “Based on the relatively low number of individuals estimated to be diagnosed with Rett syndrome each year, and because testing may already be routinely conducted in Canada to confirm the diagnosis of Rett syndrome, if trofinetide becomes funded, the provision of MECP2 testing is not anticipated to have a substantial impact on human or other health care resources.”

Source: [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1)

Additional sources: [Kim et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39255539/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Glycine-Proline-Glutamate Analogs

<a id="topic-2.2.2.1.1-1"></a>

###### Trofinetide: FDA-approved indication, formulations, and weight-based dosing

> “DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.”
> “Administer DAYBUE or DAYBUE STIX orally or via gastrostomy (G) tube twice daily, in the morning and evening, with or without food.”
> “Oral solution: 200 mg/mL of a pink to red, strawberry flavored solution. For oral solution: 5,000 mg, 6,000 mg, or 8,000 mg of white, off-white to pinkish powder with strawberry flavor, packaged in individual packets.”
> “The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown.”

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

| Patient weight | Recommended dosage |
| --- | --- |
| 9 kg to less than 12 kg | “5,000 mg twice daily” |
| 12 kg to less than 20 kg | “6,000 mg twice daily” |
| 20 kg to less than 35 kg | “8,000 mg twice daily” |
| 35 kg to less than 50 kg | “10,000 mg twice daily” |
| 50 kg or more | “12,000 mg twice daily” |

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

<a id="topic-2.2.2.1.1-2"></a>

###### Trofinetide: class and rationale as a glycine-proline-glutamate analog

> “Trofinetide is a synthetic analog of glycine–proline–glutamate, the N-terminal tripeptide of the insulin-like growth factor 1 protein, and has demonstrated clinical benefit in phase 2 studies in Rett syndrome.”

Source: [Neul et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10287558/)

<a id="topic-2.2.2.1.1-3"></a>

###### LAVENDER phase 3 trial: design and co-primary endpoints in the prescribing information

> “The efficacy of DAYBUE for the treatment of Rett syndrome was established in a 12-week randomized, double-blind, placebo-controlled study in patients with Rett syndrome 5 to 20 years of age (Study 1; NCT04181723).”
> “Patients were randomized to receive DAYBUE (N=93) or matching placebo (N=94) for 12 weeks.”
> “The co-primary efficacy measures were change from baseline after 12 weeks of treatment in the total score of the Rett Syndrome Behaviour Questionnaire (RSBQ) and the Clinical Global Impression-Improvement (CGI-I) score.”

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

<a id="topic-2.2.2.1.1-4"></a>

###### LAVENDER phase 3 trial: co-primary efficacy results at week 12

| Measure | Trofinetide (N=93) | Placebo (N=94) |
| --- | --- | --- |
| RSBQ mean baseline score (SE) | “43.7 (1.21)” | “44.5 (1.26)” |
| RSBQ mean week 12 score (SE) | “39.9 (1.38)” | “42.8 (1.42)” |
| RSBQ LS mean change from baseline to week 12 (SE) | “-4.9 (0.94)” | “-1.7 (0.90)” |
| CGI-I mean week 12 score (SE) | “3.5 (0.08)” | “3.8 (0.06)” |

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

| Endpoint | Trofinetide-placebo treatment difference, LS mean (95% CI) | p-value |
| --- | --- | --- |
| RSBQ total score change from baseline | “-3.2 (-5.7, -0.6)” | “0.018” |
| CGI-I score at week 12 | “-0.3 (-0.5, -0.1)” | “0.003” |

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

<a id="topic-2.2.2.1.1-5"></a>

###### LAVENDER phase 3 trial: effect sizes, key secondary endpoint, and disposition

> “For the coprimary efficacy endpoints, least squares mean (LSM) change from baseline to week 12 in the Rett Syndrome Behaviour Questionnaire for trofinetide versus placebo was −4.9 versus −1.7 (P = 0.0175; Cohen’s d effect size, 0.37), and LSM Clinical Global Impression–Improvement at week 12 was 3.5 versus 3.8 (P = 0.0030; effect size, 0.47).”
> “For the key secondary efficacy endpoint, LSM change from baseline to week 12 in the Communication and Symbolic Behavior Scales Developmental Profile Infant–Toddler Checklist Social Composite score was −0.1 versus −1.1 (P = 0.0064; effect size, 0.43).”
> “155 participants (82.9%) completed the study (trofinetide, n = 70 (75.3%); placebo, n = 85 (90.4%))”
> “Eighteen participants withdrew due to a TEAE (trofinetide, n = 16 (17.2%); placebo, n = 2 (2.1%)), with diarrhea being the primary TEAE leading to discontinuation (trofinetide, n = 12 (12.9%))”

Source: [Neul et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10287558/)

<a id="topic-2.2.2.1.1-6"></a>

###### LAVENDER phase 3 trial: adverse reactions in the prescribing information

| Adverse reaction | Trofinetide (N=93), % | Placebo (N=94), % |
| --- | --- | --- |
| Diarrhea | “82” | “20” |
| Vomiting | “29” | “12” |
| Fever | “9” | “4” |
| Seizure | “9” | “6” |
| Anxiety | “8” | “1” |
| Decreased appetite | “8” | “2” |
| Fatigue | “8” | “2” |
| Nasopharyngitis | “5” | “1” |

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

<a id="topic-2.2.2.1.1-7"></a>

###### Trofinetide: warnings for diarrhea, weight loss, and vomiting

> “In Study 1 [see Clinical Studies (14)] and in long-term studies, 85% of patients treated with DAYBUE experienced diarrhea. In those treated with DAYBUE, 49% either had persistent diarrhea or recurrence after resolution despite dose interruptions, reductions, or concomitant antidiarrheal therapy.”
> “In Study 1, antidiarrheal medication was used in 51% of patients treated with DAYBUE.”
> “In Study 1, 12% of patients treated with DAYBUE experienced weight loss of greater than 7% from baseline, compared to 4% of patients who received placebo. In long-term studies, 2.2% of patients discontinued treatment with DAYBUE due to weight loss.”
> “Aspiration and aspiration pneumonia have been reported following vomiting in patients being treated with DAYBUE.”
> “Eighteen patients (19%) receiving DAYBUE had adverse reactions that led to withdrawal from the study. The most common adverse reaction leading to discontinuation of treatment with DAYBUE was diarrhea (15%).”

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

<a id="topic-2.2.2.1.1-8"></a>

###### LILAC open-label extension: 40-week safety and efficacy

> “Females with Rett syndrome aged 5-21 years received open-label treatment with trofinetide for 40 weeks.”
> “Overall, 154 participants were enrolled and treated with trofinetide in LILAC. The most common adverse events in LILAC were diarrhea (74.7%), vomiting (28.6%), and COVID-19 (11.0%). Diarrhea was the most common adverse event leading to treatment withdrawal (21.4%).”
> “The Rett Syndrome Behaviour Questionnaire mean score (standard error) improvement from the LAVENDER baseline to week 40 in LILAC was -7.3 (1.62) and -7.0 (1.61) for participants treated with trofinetide and placebo in LAVENDER, respectively.”

Source: [Percy et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38917793/)

<a id="topic-2.2.2.1.1-9"></a>

###### LILAC-2 open-label extension: 32-month safety and efficacy

> “In total, 77 participants were enrolled in LILAC-2. The most common AEs were diarrhea (53.2%), COVID-19 (27.3%), and vomiting (19.5%). The mean (standard error [SE]) change in RSBQ score from LAVENDER baseline to week 104 of LILAC-2 was -11.8 (2.45).”
> “Most caregivers (96%; n = 24/25) were satisfied or very satisfied with the benefits of trofinetide.”

Source: [Percy et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39025065/)

<a id="topic-2.2.2.1.1-10"></a>

###### DAFFODIL open-label study: girls aged 2 to 4 years

> “DAFFODIL was a phase 2/3, open-label study of trofinetide consisting of two treatment periods (12 weeks [period A] and ∼21 months [period B]).”
> “Fifteen participants were enrolled. Overall, the most common TEAEs were diarrhea (80.0%) and vomiting (53.3%), which were mild or moderate in severity. Steady-state exposure at clinical doses fell within the target exposure range.”

Source: [Percy et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40043705/)

> “Use of DAYBUE or DAYBUE STIX in patients 2 to 4 years of age is supported by evidence from Study 1 and pharmacokinetic and safety data in 15 pediatric patients 2 to 4 years of age treated with DAYBUE”
> “Safety and effectiveness in pediatric patients less than 2 years of age have not been established.”

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

<a id="topic-2.2.2.1.1-11"></a>

###### LOTUS real-world study: dosing, caregiver-reported benefit, and diarrhea

> “Overall, 227 caregivers participated in this follow‐up. The median trofinetide dose at week 1 was 36.0% of the target dose and increased to over 80% by week 10 onwards; 55.2% of patients took the full trofinetide recommended daily dose.”
> “The incidence of diarrhea varied from weeks 1 to 12 (23%–50%) and months 4 to 12 (26%–38%); most reports of diarrhea were contained inside the patient's diaper.”

Source: [Cosand et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875184/)

<a id="topic-2.2.2.1.1-12"></a>

###### Expert consensus: trofinetide as first-line therapy and titration

> “Two rounds of assessments were completed by 25 respondents in each round, resulting in agreement ≥ 75% being reached across the final statement set. The consensus supports trofinetide as the standard of care for eligible patients with early initiation and an individualized approach to titration to maximize efficacy and tolerability.”
> “Agreement (88%–100%) across statements 1–2 and 5–7 supports trofinetide as first‐line therapy in the standard of care for eligible patients with RTT aged ≥ 2 years”
> “To minimize the impact of side effects, this consensus supports initiation at 5–10 mL (1000–2000 mg) BID or 25%–50% of the recommended weight‐banded dose BID and then titrate carefully at 5 mL (1000 mg) increase every 1–2 weeks based on tolerance.”
> “Respondents supported maintaining treatment with trofinetide for at least 6 months post titration to determine efficacy”

Source: [Prange et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13359341/)

<a id="topic-2.2.2.1.1-13"></a>

###### Expert consensus: selected statements and overall agreement

| Consensus statement | Overall agreement |
| --- | --- |
| “Trofinetide should be part of the standard of care for RTT individuals at least 2 years of age, as indicated” | “88%” |
| “Trofinetide is not typically initiated at the full weight‐banded dose” | “96%” |
| “Consider discontinuing all constipation medications prior to initiating trofinetide” | “84%” |
| “The healthcare provider should adapt the titration schedule first before introducing additional medications, such as loperamide, to manage diarrhea” | “80%” |
| “Trofinetide can be safely discontinued without tapering” | “96%” |

Source: [Prange et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13359341/)

<a id="topic-2.2.2.1.1-14"></a>

###### European Union authorization: neurobehavioural symptoms, age 5 years and older

> “Daybu is a medicine used for the treatment of neurobehavioural symptoms of Rett syndrome in adults and children aged 5 years and older.”
> “The Agency considered that although these improvements were small, they were relevant in the context of a rare and serious disorder such as Rett syndrome.”
> “Daybu received a marketing authorisation valid throughout the EU on 20 August 2026.”

Source: [EMA Daybu EPAR (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/daybu)

Additional sources: [ClinicalTrials.gov NCT04181723](https://clinicaltrials.gov/study/NCT04181723); [ClinicalTrials.gov NCT04279314](https://clinicaltrials.gov/study/NCT04279314); [ClinicalTrials.gov NCT04776746](https://clinicaltrials.gov/study/NCT04776746); [ClinicalTrials.gov NCT04988867](https://clinicaltrials.gov/study/NCT04988867); [Neul et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35149233/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Antiseizure Medications

<a id="topic-2.2.2.1.2-1"></a>

###### Consensus guideline: neurology referral and antiseizure medication monitoring

> “Refer to neurologist for seizures and spells suspicious for seizures, with follow-up every 6 months if treated with an anticonvulsant. It is difficult to differentiate between a non-epileptic Rett spell and a seizure (both may be present).”
> “If the individual’s weight fluctuates (more than 10%–20%), request the neurologist to consider adjusting anticonvulsant doses accordingly. Laboratory follow-up as needed for use of antiseizure medications.”
> “but there have been no randomised controlled trials of specific anticonvulsants for RTT.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.2-2"></a>

###### Natural History Study: remission and medication withdrawal

> “Although 248 of those with classic Rett syndrome and a history of seizures were in terminal remission at last contact, only 74 (12% of those with a history of epilepsy) were seizure free and off anti-seizure medication.”
> “Notably, persistent drug resistant epilepsy without remission is not the most common pattern, only affecting 16% of those with classic Rett syndrome, a figure less than half that of the Italian and Australian studies.”

Source: [Tarquinio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5278305/)

<a id="topic-2.2.2.1.2-3"></a>

###### Antiseizure drug selection: comparative evidence and adverse-effect considerations

> “Although cases and retrospective studies document efficacy of specific medications in Rett syndrome, no systematic study has demonstrated superiority of a specific medication or class of medications to treat epilepsy in Rett syndrome”
> “No specific medications are contraindicated in Rett syndrome; however, the issue of bone health is an important consideration when prescribing anti-seizure drugs.”
> “In summary, when seizures are concluded to be epileptic in origin and anti-seizure drugs are initiated, the side effect profiles of medications should be considered carefully, and medications, which can cause behavioural issues (e.g. levetiracetam), anorexia and nephrolithiasis (e.g. topiramate), QT interval prolongation (e.g. felbamate), or marked sedation (e.g. benzodiazepines), should be used with caution.”

Source: [Tarquinio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5278305/)

<a id="topic-2.2.2.1.2-4"></a>

###### Review: lack of comparative studies and non-pharmacological options for refractory epilepsy

> “There are problems in evaluating the treatment efficiency of AED due to the general lack of comparative studies and the number of different AED used in monotherapy or combination treatment in RTT.”
> “Due to limited experience of epilepsy treatment in RTT, no definite recommendation regarding anticonvulsants is currently available.”
> “The ketogenic diet and vagal nerve stimulation have been reported to be effective treatment options in some refractory RTT cases.”

Source: [Krajnc (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4468994/)

<a id="topic-2.2.2.1.2-5"></a>

###### Antiseizure medications prescribed in a US electronic health record cohort

| Antiseizure medication | Participants with epilepsy, n (%) (N = 59) |
| --- | --- |
| Levetiracetam | “27 (45.8%)” |
| Clonazepam | “22 (37.3%)” |
| Oxcarbazepine | “18 (30.5%)” |
| Lamotrigine | “15 (25.4%)” |
| Valproate or valproic acid | “15 (25.4%)” |
| Topiramate | “10 (16.9%)” |
| Lacosamide | “7 (11.9%)” |

Source: [Rashid et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12549289/)

<a id="topic-2.2.2.1.2-6"></a>

###### Drug-resistant epilepsy and absence of first-line recommendations

> “While AEDs are effective therapy, either as monotherapy or in combination, for many individuals who have seizures in RTT, 20–40% experience drug-resistant epilepsy”
> “Due to the non-localized nature of epilepsy in RTT, unlike individuals with other types epilepsy (i.e., focal onset epilepsy), surgical treatments are generally not effective for drug-resistant epilepsy in RTT”

Source: [Rashid et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12549289/)

<a id="topic-2.2.2.1.2-7"></a>

###### Cannabidiol for drug-resistant epilepsy: Italian multicenter cohort

> “We enrolled 27 subjects (26 females), carrying a MECP2 genetic variant (14 subjects, 51.9%) or a CDKL5 genetic variant (13 subjects, 48.1%).”
> “Although not reaching a significant statistical effect, CBD reduced the incidence of seizures with respect to the baseline in 18/27 (66.6%) subjects, with 7 (25.9%) showing a seizure reduction >75%, and 11 (40.7%) >50%.”
> “The most relevant adverse events were somnolence seen in 3 subjects, irritability/agitation in 2 subjects, loss of appetite in 2 subjects, and insomnia in 1 individual.”

Source: [Vignoli et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12362169/)

<a id="topic-2.2.2.1.2-8"></a>

###### Cannabidiol as adjunctive therapy: French single-center cohort

> “In our cohort, 26 patients had associated epilepsy (26/46 [56%]), and 10/26 (38%) were treated with CBD, in combination with clobazam in 50% of cases.”
> “CBD reduced the incidence of seizures in seven out of 10 patients (70%) with one seizure‐free patient, two patients with a reduction of seizures of more than 75%, and four patients with a decrease of more than 50%.”

Source: [Desnous et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10839357/)

<a id="topic-2.2.2.1.2-9"></a>

###### Rescue therapy: diazepam nasal spray for seizure clusters

> “Age- and weight-based doses of diazepam nasal spray (5–20 mg) were administered to patients (aged 6–65 years) for seizure clusters.”
> “All caregivers felt diazepam nasal spray was very/extremely easy to use; 63.6% were able to return to normal activities within an hour of administration.”
> “Diazepam nasal spray has safety and effectiveness profiles consistent with the full study population and was easy to use.”

Source: [Tarquinio et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12970060/)

<a id="topic-2.2.2.1.2-10"></a>

###### Trofinetide with concomitant antiseizure medication

> “The most frequently used concomitant medications in the trofinetide and placebo groups were antiseizure medication (64.5% and 72.3%, respectively) and drugs for constipation (60.2% and 70.2%)”

Source: [Neul et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10287558/)

> “Patient history of seizures should be taken prior to initiating trofinetide, if possible”
> “the majority will not experience changes in seizures, while the minority may experience improvement or worsening during treatment, depending on the individual patient”

Source: [Prange et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13359341/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Gastrointestinal and Nutritional Management

<a id="topic-2.2.2.1.3-1"></a>

###### Consensus guideline: constipation and gastro-oesophageal reflux

> “Laxatives (polyethylene glycol, magnesium hydroxide, glycerin or bisacodyl suppositories) are often part of long-term treatment with a goal of one soft bowel movement per day.”
> “Proton pump inhibitor or H2 blockers are used empirically. Referral to gastroenterologist may be necessary to rule out complications such as oesophagitis, ulcer, strictures or Barrett’s oesophagus.”
> “Gall bladder dysfunction, screened by abdominal ultrasound, should be considered. Referral to surgery for cholecystectomy may be necessary for symptomatic gallstones or biliary dyskinesia.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.3-2"></a>

###### Consensus guideline: poor weight gain, prolonged feeding, and swallowing difficulties

> “Fatigue and irritability may be signs that dietary requirements are not being met; consider energy dense foods (oils, syrups, avocado), and gastroenterologist and nutrition consults. Gastrostomy button may be needed to maintain growth; counsel families that use of a gastrostomy button does not preclude oral feeding as long as oral feeding is safe.”
> “Long feeding times (more than 30 min) can affect quality of life for patient and family; this may be an indication that a gastrostomy button is needed.”
> “In some cases, thickeners for liquids may be helpful to prevent aspiration versus need for a gastrostomy button.”
> “Consider nutrition-related laboratory screening (yearly): complete blood count, electrolyte panel, 25-OH vitamin D, fasting lipids.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.3-3"></a>

###### Expert recommendations: proactive management of gastrointestinal comorbidities

> “Although gastrointestinal (GI) comorbidities are experienced by over 90% of individuals with Rett syndrome (RTT), a neurodevelopmental disorder associated with mutations in the MECP2 gene, many neurologists and pediatricians do not rank the management of these comorbidities among the most important treatment goals for RTT.”
> “The authors recommend a proactive approach to management of symptomatic GI comorbidities and drug-associated symptoms in RTT to enhance drug tolerance and improve the quality of life of affected individuals.”

Source: [Motil et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38869952/)

<a id="topic-2.2.2.1.3-4"></a>

###### Real-world management by US physicians: constipation, growth, and reflux

> “For the treatment of constipation, neurologists most commonly referred patients to a dietician or to a gastroenterologist (57.1% each), while pediatricians were most likely to provide dietary recommendation (91.3%), refer to a dietician (78.3%), and prescribe laxatives (69.6%).”
> “Among the 10 pediatricians who responded, all (100%) prescribed anti-reflux medication, 8 (80%) referred to a dietician, and 7 (70%) provided dietary recommendations and advice.”
> “Management of GI issues was ranked among the five most important treatment goals by 3 (5.9%) neurologists and 4 (8.2%) pediatricians surveyed.”

Source: [May et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10842289/)

<a id="topic-2.2.2.1.3-5"></a>

###### Gastrostomy: utilization, weight gain, and family satisfaction in an Australian population cohort

> “Sixty-six females (28.8%) had a gastrostomy”
> “Weight-for-age z-scores increased by 0.86 (95% CI 0.41, 1.31) approximately 2 years after surgery.”
> “Families were satisfied with gastrostomy and felt less anxious about the care of their child.”

Source: [Downs et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603139/)

<a id="topic-2.2.2.1.3-6"></a>

###### Gastrostomy: body mass index and mortality in a longitudinal cohort

> “Nearly one-third (30.3%) of the cases underwent gastrostomy placement.”
> “Nevertheless, among those at risk of suboptimal weight, the all-cause mortality rate was greater in those who had gastrostomy placement compared with those who had not (hazard ratio 4.07, 95% CI 1.96-8.45).”
> “Gastrostomy placement was associated with improvement in BMI in females with Rett syndrome, but its long-term impact on individuals and their families is unclear.”

Source: [Wong et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29941161/)

<a id="topic-2.2.2.1.3-7"></a>

###### Multidisciplinary clinic cohort: aperients and gastrostomy

> “Constipation was reported in 65% and all required specific treatment with aperients.”
> “Gastrostomy feeding tube placement was required for 24 (23.3%) girls at a mean age of 8 years (SD 4.2 years).”

Source: [Vilvarajan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10454341/)

<a id="topic-2.2.2.1.3-8"></a>

###### Systematic review: enteral feeding utilization across studies

> “Eighteen studies examined assisted interventions, showing enteral feeding utilization rates from 2.0% to 52.0%.”

Source: [Rashid et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396111/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Scoliosis Management and Spinal Surgery

<a id="topic-2.2.2.1.4-1"></a>

###### Consensus guideline: surveillance and referral thresholds

> “Increased risk of neuromuscular scoliosis after age 6; risk typically abates after puberty. This can progress rapidly if present, necessitating reobservation every 6 months if present. Supine X-ray and orthopaedic referral when scoliotic curvature greater than 20°; correction may be indicated when greater than 40°.”
> “Surveillance for scoliosis becomes an important preventive measure; some children (~20%) ultimately require spinal surgery for this comorbidity.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.4-2"></a>

###### Consensus guideline: scoliosis management across the lifespan

> “The second draft comprised 88 items with agreement to strong agreement achieved on 85, to form the final guideline document.”
> “A comprehensive, life-span approach to the management of scoliosis in Rett syndrome is recommended that takes into account factors such as physical activity, posture, nutritional and bone health needs.”
> “Surgery should be considered when the Cobb angle is approximately 40 degrees to 50 degrees and must be supported by specialist management of anesthesia, pain control, seizures, and early mobilization.”

Source: [Downs et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19644320/)

<a id="topic-2.2.2.1.4-3"></a>

###### Natural History Study: frequency of surgery and recommendations for bracing and surgery

> “913 females with classic RTT were included.”
> “168 (18%) had surgical correction.”
> “In terms of the actual age distribution for the 168 participants who had surgical correction, the majority (86%) occurred between age 9 and 15, the median age was 12 years (min=5, max=21).”
> “As such, when curves reach 25°, we recommend implementation of bracing in hopes of retarding or minimizing further progression. However, once the curve reaches 40° or more, we strongly promote surgical intervention.”

Source: [Killian et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5461984/)

<a id="topic-2.2.2.1.4-4"></a>

###### Spinal fusion and survival in severe scoliosis

> “After adjusting for mutation type and age of scoliosis onset, the rate of death was lower in the surgery group (hazard ratio [HR] 0.30, 95% confidence interval [CI] 0.12-0.74; p=0.009) compared to those without surgery.”
> “With appropriate cautions, spinal fusion confers an advantage to life expectancy in Rett syndrome.”

Source: [Downs et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26661519/)

<a id="topic-2.2.2.1.4-5"></a>

###### US national trends and perioperative outcomes of posterior spinal fusion

> “Among 220 patients with RAS, 216 (98.2%) were females (mean age at surgery: 12.3±3.3 yr).”
> “RTT diagnosis independently predicted higher odds of any complications (odds ratio: 1.98, P < 0.001) and increased length of stay (odds ratio: 1.18, P = 0.009) for admissions for PSF.”
> “Surgical treatment for RAS is rare but increased over a 19-year period.”

Source: [Stone et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37642479/)

<a id="topic-2.2.2.1.4-6"></a>

###### Growth-friendly surgery and posterior spinal fusion in early onset scoliosis

> “The study included 15 females with Rett syndrome. Five patients had MCGR and 10 underwent PSF.”
> “There was one complication per group.”
> “Both MCGR and PSF effectively control scoliosis in RS patients. PSF provides superior coronal curve correction, while MCGR promotes spinal growth.”

Source: [Patel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40820925/)

<a id="topic-2.2.2.1.4-7"></a>

###### Orthotics and timing of spinal fusion

> “Scoliosis in individuals with Rett syndrome often does not respond to orthotics.”
> “Surgeons usually try to wait until the child is at least 10 years of age before performing spinal fusion. They may often recommend bracing, physiotherapy and physical activity to delay surgery in order to allow for as much growth as possible.”

Source: [Maheshwari (2018)](https://www.ai-online.info/images/ai-ausgabe/2018/04-2018/orphan-supplement-6-2018/2018_4_S117-S124_Rett%20syndrome.pdf)

<a id="topic-2.2.2.1.4-8"></a>

###### Multidisciplinary clinic cohort and systematic review: rates of scoliosis surgery

> “Scoliosis was diagnosed in 61 girls (59.2%) with 12 (11.7%) requiring spinal surgery at a median age of 12.5 years (IQR 12–15 years).”

Source: [Vilvarajan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10454341/)

> “Nine studies reported surgical procedures, with 1.2%–50.0% of patients requiring scoliosis surgery.”

Source: [Rashid et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396111/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Bone Health Management

<a id="topic-2.2.2.1.5-1"></a>

###### Consensus guideline: fracture risk, densitometry, calcium, and vitamin D

> “There is higher risk of fracture due to immobility and use of anticonvulsants. If fracture occurs, consider bone density (DEXA) scan and referral to endocrine specialist (in addition to aggressive screen of calcium, vitamin D intake and 25-OH vitamin D levels).”
> “Ensure supplemental vitamin D intake: 600–1000 IU or more daily. Target serum levels of 25-OH-vitamin D greater than 30–40 ng/mL.”
> “With age, concern for low bone mineral mass coupled with long-term use of particular anticonvulsants raises the risks for osteoporosis and bone fractures”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.5-2"></a>

###### Bone health guideline: assessment and first-line interventions

> “Agreement was reached on 39 statements which were formulated from 41 statements and 11 questions.”
> “A baseline densitometry assessment should be performed with accommodations made for size, with the frequency of surveillance determined according to individual risk.”
> “Increasing physical activity and initiating calcium and vitamin D supplementation when low are the first approaches to optimizing bone health in Rett syndrome. If individuals with Rett syndrome meet the ISCD criterion for osteoporosis in children, the use of bisphosphonates is recommended.”

Source: [Jefferson et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4743907/)

<a id="topic-2.2.2.1.5-3"></a>

###### Bone health guideline: non-pharmacological and pharmacological statements with panel agreement

| Intervention | Statement | Panel agreement, n/N (%) |
| --- | --- | --- |
| Physical activity | “Increase physical activity in order to increase muscle strength and bone density” | “34/34 (100)” |
| Standing frame | “Use a standing frame for at least 30 minutes a day” | “28/33 (84.8)” |
| Targeted exercise | “Where mobility is limited, targeted exercise such as body weight supported treadmill or assisted walking is recommended” | “31/32 (96.9)” |
| Dietary calcium | “If calcium intake is low, increase dietary intake of calcium rich or calcium fortified foods” | “31/32 (96.9)” |
| Bisphosphonate indication | “Bisphosphonates should be used if the International Society for Clinical Densitometry criteria for osteoporosis in children and adolescents are fulfilled” | “17/23 (73.9)” |
| Bisphosphonate reassessment | “Reassess bone mineral content and areal bone mineral density one year after Bisphosphonate therapy to decide on further therapy” | “24/26 (92.3)” |
| Hormonal contraception | “If hormonal intervention for regulation of the menstrual cycle is needed, use of Depot medroxyprogesterone acetate (DMPA) should be avoided” | “21/21 (100)” |

Source: [Jefferson et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4743907/)

<a id="topic-2.2.2.1.5-4"></a>

###### Bone health guideline: limited evidence for bisphosphonates

> “Whilst the group agreed that bisphosphonate therapy may be indicated, several panel members did make note of the lack of evidence for efficacy and safety of bisphosphonate use in RTT and that its mechanism of action may be different from disorders such as osteogenesis imperfecta in which its use is frequent”

Source: [Jefferson et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4743907/)

<a id="topic-2.2.2.1.5-5"></a>

###### Zoledronate: retrospective national center cohort

> “Nine patients (23%) received zoledronate, for a mean 2 years. The mean age at zoledronate initiation was 9.7 ± 2.3 years. Four completed two DXA scans (pre- and post-treatment); the mean BMD Z-score improved from −2.2 ± 0.9 to −1.4 ± 0.9 after treatment.”
> “Poor L1–4 BMD Z-scores were associated with poor mobility scores (p = 0.05) and valproate treatment (p = 0.016).”

Source: [Levy-Shraga et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12602358/)

<a id="topic-2.2.2.1.5-6"></a>

###### Zoledronic acid: annual infusion in children with cerebral palsy and Rett syndrome

> “27 children under 18 years (19 with cerebral palsy and 8 girls with Rett syndrome confirmed by MCEP2 mutation) were treated with an annual injection of 0.1 mg/kg (max 4 mg) of ZA.”
> “No fractures have been observed in our cohort since the first infusion.”
> “Side effects (flu-like syndrome and hypocalcemia) were more common in younger patients and after the first infusion.”

Source: [Wiedemann et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30554334/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Psychotropic Medications for Anxiety and Behavior

<a id="topic-2.2.2.1.6-1"></a>

###### Consensus guideline: screening for anxiety and depression and selective serotonin reuptake inhibitors

> “Screen for caregiver impressions of anxiety and depression, such as withdrawal; these may become more prominent with age or in individuals with milder clinical presentations. Identify possible contributors (eg, sedating medications, decreased social interaction, limited access to engaging activities). Consider treatment with a selective serotonin reuptake inhibitor such as escitalopram which may have a lower risk of inducing a prolonged QTc interval.”
> “Families should be encouraged to disclose use of alternative medications (cannabis, oils and so on) to all specialists.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.6-2"></a>

###### Natural History Study: absence of anxiety management guidelines

> “In spite of the general impression that anxiety-like behavior is common in individuals with RTT, no systematic studies of anxiolytics use have been reported in this population and guidelines for clinical management of anxiety in RTT do not exist.”

Source: [Buchanan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9107202/)

<a id="topic-2.2.2.1.6-3"></a>

###### Natural History Study: frequency of anxiolytic and SSRI use

> “Parental reports and medication logs provided data from 1380 females with RTT participating in two iterations of the multicenter U.S. RTT Natural History Study (RNHS) from 2006 to 2019.”
> “Parents directly reported treatment for anxious or nervous behavior in 16.6% of participants in the second iteration with most reporting good control of the behavior (71.6%).”
> “15.0% of participants in the first and 14.5% in the second (P = 0.835). The most commonly used drugs were escitalopram, sertraline, fluoxetine, and buspirone.”
> “Based on medication logs, SSRI use for any indication was reported for 13.1% of participants in the first iteration and 11.0% in the second iteration (P = 0.414).”
> “Increased use of anxiolytics and selective serotonin reuptake inhibitors (SSRIs) was related to more frequent anxiety-like behaviors (P < 0.001), older age (P < 0.001), and mild MECP2 variants (P = 0.002).”

Source: [Buchanan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9107202/)

<a id="topic-2.2.2.1.6-4"></a>

###### Natural History Study: efficacy and safety not assessed

> “The present study was not designed to assess the efficacy or safety of these medications, but parent report indicates that most treated participants have good control.”

Source: [Buchanan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9107202/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Sleep Management

<a id="topic-2.2.2.1.7-1"></a>

###### Consensus guideline: melatonin, trazodone, clonidine, bed safety, iron, and sleep study

> “Circadian rhythm is often disrupted; consider melatonin to initiate sleep and trazodone or clonidine to maintain asleep. Patient may be getting out of bed, which could be unsafe; consider a tent-style bed or similar engineering controls to keep child in bed and safe. Consider ferritin, serum iron, total iron binding capacity and transferrin levels if there is disrupted sleep or concerns for restless leg syndrome and need for iron replacement. Consider overnight sleep study for snoring or pauses in breathing.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.7-2"></a>

###### Sleep hygiene and medication use: International Rett Syndrome Phenotype Database

> “Sleep disturbances are debilitating for individuals with Rett syndrome (RTT) and their families yet the evidence base for management is poor.”
> “Data were provided by 364/461 (79%) families with a child with RTT and registered with the International RTT Phenotype Database.”
> “Better use of sleep hygiene practices was associated with lower odds of moderate/major impact on the family (odds ratio 0.60, 95% confidence intervals [CIs] 0.37, 0.98) and lower DIMS scores (geometric mean ratio 0.86, 95%CI 0.80, 0.92) compared with poorer use after adjusting for covariates.”
> “Attention to sleep hygiene remains an important management strategy for sleep problems in RTT. Further prospective research is required to investigate efficacy of pharmaceutical treatments.”

Source: [Boban et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29704311/)

<a id="topic-2.2.2.1.7-3"></a>

###### Melatonin: double-blind, placebo-controlled crossover trial

> “Subsequently, patients underwent a 4-week melatonin treatment period in a double-blind, placebo-controlled, crossover protocol that employed a 1-week washout between treatment trials. Melatonin doses ranged from 2.5 to 7.5 mg, based upon individual body weight.”
> “Melatonin significantly decreased sleep-onset latency to (mean +/- SE) 19.1+/-5.3 minutes (P<0.05) during the first 3 weeks of treatment.”
> “Finally, a 4-week administration of melatonin appears to be a safe treatment as no adverse side effects were detected, yet long-term effects of chronic melatonin use in pediatric patients are unknown at this time.”

Source: [McArthur and Budden (1998)](https://pubmed.ncbi.nlm.nih.gov/9566656/)

<a id="topic-2.2.2.1.7-4"></a>

###### Multidisciplinary clinic cohort: sleep medications prescribed

> “Melatonin was the most common medication prescribed in our cohort and is most helpful for sleep initiation [28]. Other medications commonly prescribed for management of sleep disturbance included clonidine, chloral hydrate, Phenergan and risperidone [28].”

Source: [Vilvarajan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10454341/)

<a id="topic-2.2.2.1.7-5"></a>

###### Obstructive sleep apnea on polysomnography and screening

> “Six of thirteen participants had obstructive sleep apnea, which was worse during rapid eye movement (REM) sleep with associated hypoxemia and disruptions in sleep architecture.”
> “This suggests that providers should routinely screen for sleep problems and implement interventions that can positively impact the quality of life of individuals with Rett syndrome and their families.”

Source: [Peters et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12354067/)

<a id="topic-2.2.2.1.7-6"></a>

###### Narrative review: sleep hygiene as first-line therapy

> “Evidence on management of sleep disorders is lacking, as no algorithms are available, the choice of therapy depends on each case (15, 95).”
> “To date, sleep hygiene remains the first-line therapy. Although melatonin has been shown to be effective in improving total sleep time and sleep onset latency, the literature on drug efficacy and safety is poor and drug trials need to be designed.”

Source: [Tascini et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8923297/)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Rehabilitative and Communication Therapies

<a id="topic-2.2.2.1.8-1"></a>

###### Consensus guideline: therapies to maintain and regain skills

> “Skills can be maintained and possibly regained with vigorous therapies. Therapies to consider: speech therapy, feeding therapy, occupational therapy, augmentative communication therapy, vision therapy, hippotherapy (horse) and swim/pool therapy.”
> “Therapies for RTT should include occupational, physical, speech, swallowing and augmentative communication. Therapy that maximises physical activities should be lifelong, as these will minimise long-term complications and maximise long-term potentials.”
> “Consider occupational therapy (OT) and physical therapy (PT) consults for bracing and splinting. Consider neurology and physiatry consults for neuromuscular blockade or other medications to improve tone.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.8-2"></a>

###### Consensus guideline: augmentative and alternative communication and eye gaze devices

> “Alternative and augmentative communication assessments are needed. While this can be done by some speech therapists, a specific referral may be needed. Since eye gaze is typically the most effective form of communication, special eye gaze devices can give individuals a voice. These referrals should be made as early as possible to coincide with typical language development.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.8-3"></a>

###### Communication guideline: international Delphi consensus

> “All statements that reached a pre-determined threshold of ≥70% agreement were incorporated into guidelines that consist of 268 statements and recommendations relating to (a) rights of the individual; (b) beliefs and attitudes of communication partners; (c) professional knowledge and team work; (d) strategies to optimize engagement; (e) assessment; and (f) intervention (targets and goals, techniques), including the use of AAC.”
> “To date, this project is the largest of its kind, with 650 participants from 43 countries contributing to development of consensus-based guidelines for Rett syndrome.”

Source: [Townend et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32720526/)

<a id="topic-2.2.2.1.8-4"></a>

###### Systematic review: communication intervention studies, 2010 to 2022

> “Across the 16 studies, intervention was provided to a total of 100 participants from 3 to 47 years of age. Half of the studies used systematic instruction to teach aided AAC.”
> “Positive outcomes (e.g., using AAC devices to make requests and/or initiate social-communication interactions) were reported in 13 of the studies.”

Source: [Sigafoos et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37526342/)

<a id="topic-2.2.2.1.8-5"></a>

###### Eye gaze technology: family experiences in the Netherlands

> “20 respondents were using or had previous experience of using an eye gaze system at the time of the survey, 28 of those with no prior experience wanted to try a system in the future. Following a trial period, 11 systems had been funded through health insurance for long-term use and two families had decided a system was not appropriate for them.”
> “The majority of families reported progress in their child’s skills with longer term use.”

Source: [Townend et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4785214/)

<a id="topic-2.2.2.1.8-6"></a>

###### Environmental enrichment: individually randomised stepped wedge trial

> “A genetically variable group of 12 girls with a MECP2 mutation and younger than 6 years participated in a modified individually randomised stepped wedge design study.”
> “The intervention comprised motor learning and exercise supplemented with social, cognitive and other sensory experiences over a six-month period.”
> “Adjusting for covariates, the enriched environment was associated with improved gross motor skills (coefficient 8.2, 95%CI 5.1, 11.2) and a 321.4 ng/ml (95%CI 272.0, 370.8) increase in blood BDNF levels after 6 months of treatment. Growth, sleep quality and mood were unaffected.”

Source: [Downs et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5764021/)

<a id="topic-2.2.2.1.8-7"></a>

###### Systematic review: physical therapy approaches

> “Nine approaches to physical therapy for patients with Rett syndrome were identified: applied behavior analysis, conductive education, environmental enrichment, traditional physiotherapy with or without aids, hydrotherapy, treadmill, music therapy, computerized systems, and sensory-based treatment. It has been reported that patients had clinically benefited from the analysed approaches despite the fact that they did not have strong research evidence.”

Source: [Fonzo et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7407501/)

<a id="topic-2.2.2.1.8-8"></a>

###### Systematic review: utilization of physical, occupational, and speech therapy

> “Six studies examined ancillary service use, where PT utilization ranged from 24.4% to 100.0% and occupational therapy (OT) ranged from 11.5% to 91.7%. Pediatric patients demonstrated a two- to fourfold higher utilization of PT and OT services compared to adults.”
> “The two US-based retrospective claims analyses reported ST utilization rates of 74.1% and 13.3%, respectively [4, 11].”
> “For example, rehabilitation therapies such as PT, OT, and ST are commonly recommended as part of supportive management based on functional needs, but there is little RTT-specific evidence to define whether ongoing, episodic, intensive, or consultative therapy models are optimal at different ages [12, 37].”

Source: [Rashid et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396111/)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Limitations of Current Therapies

<a id="topic-2.2.2.1.9-1"></a>

###### Summary: what current options treat

- Trofinetide is indicated in the United States for Rett syndrome in adults and pediatric patients 2 years of age and older, and its mechanism of action in Rett syndrome is unknown. An expert consensus of 25 respondents supports it as first-line therapy for eligible patients aged 2 years or older. The European Union authorization covers the neurobehavioural symptoms of Rett syndrome in patients aged 5 years and older.
- The other options described in the sources address individual comorbidities: antiseizure medications for seizures; laxatives, acid suppression, and gastrostomy for gastrointestinal and nutritional problems; bracing and spinal surgery for scoliosis; physical activity, calcium, vitamin D, and bisphosphonates for bone health; selective serotonin reuptake inhibitors for anxiety; melatonin, trazodone, or clonidine for sleep; and physical, occupational, speech, and augmentative communication therapies.

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf); [Prange et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13359341/); [EMA Daybu EPAR (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/daybu); [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/); [Jefferson et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4743907/); [Killian et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5461984/)

<a id="topic-2.2.2.1.9-2"></a>

###### Summary: size of the trofinetide effect

- In the 12-week randomized, double-blind, placebo-controlled study that established efficacy (Study 1 in the prescribing information), participants aged 5 to 20 years were randomized to trofinetide (N=93) or placebo (N=94). The least squares mean change in RSBQ total score was -4.9 with trofinetide and -1.7 with placebo, a difference of -3.2 (95% CI -5.7 to -0.6; p = 0.018; Cohen's d effect size 0.37). The mean CGI-I score at week 12 was 3.5 against 3.8, a difference of -0.3 (95% CI -0.5 to -0.1; p = 0.003; effect size 0.47). The key secondary endpoint, the Communication and Symbolic Behavior Scales Developmental Profile Infant-Toddler Checklist Social Composite score, changed by -0.1 against -1.1 (P = 0.0064; effect size 0.43).
- The European Medicines Agency described the improvements as small and considered them relevant for a rare and serious disorder.
- In open-label extensions, the mean RSBQ improvement from the LAVENDER baseline was -7.3 (1.62) and -7.0 (1.61) at week 40 of LILAC (154 participants) for those given trofinetide and placebo in LAVENDER, and -11.8 (2.45) at week 104 of LILAC-2 (77 participants).

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf); [Neul et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10287558/); [EMA Daybu EPAR (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/daybu); [Percy et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38917793/); [Percy et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39025065/)

<a id="topic-2.2.2.1.9-3"></a>

###### Summary: trofinetide tolerability and discontinuation

- In Study 1, diarrhea occurred in 82% of participants receiving trofinetide and 20% receiving placebo, and vomiting in 29% and 12%. Across Study 1 and long-term studies, 85% of trofinetide-treated patients had diarrhea, and 49% had persistent or recurrent diarrhea despite dose interruptions, reductions, or antidiarrheal therapy; 51% used antidiarrheal medication in Study 1. Weight loss greater than 7% occurred in 12% receiving trofinetide and 4% receiving placebo in Study 1, and 2.2% discontinued for weight loss in long-term studies. Aspiration and aspiration pneumonia have been reported after vomiting.
- The two sources give different withdrawal counts for the 12-week study: the prescribing information reports 18 patients (19%) receiving trofinetide who withdrew because of adverse reactions, most often diarrhea (15%), and the trial publication reports 16 (17.2%) receiving trofinetide and 2 (2.1%) receiving placebo who withdrew because of a treatment-emergent adverse event, with diarrhea leading to discontinuation in 12 (12.9%). The study was completed by 70 (75.3%) participants receiving trofinetide and 85 (90.4%) receiving placebo.
- In LILAC, diarrhea occurred in 74.7% and was the most common adverse event leading to withdrawal (21.4%). In a follow-up of 227 caregivers, the median dose at week 1 was 36.0% of the target dose, rising to over 80% from week 10, 55.2% of patients took the full recommended daily dose, and diarrhea incidence ranged from 23% to 50% during weeks 1 to 12. The expert consensus recommends starting at 25% to 50% of the weight-banded dose and titrating every 1 to 2 weeks.

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf); [Neul et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10287558/); [Percy et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38917793/); [Cosand et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875184/); [Prange et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13359341/)

<a id="topic-2.2.2.1.9-4"></a>

###### Summary: age range of trofinetide evidence

- The randomized evidence comes from participants aged 5 to 20 years, and LILAC enrolled females aged 5 to 21 years. Use in patients aged 2 to 4 years is supported by the randomized study together with pharmacokinetic and safety data in 15 patients aged 2 to 4 years. The open-label DAFFODIL study enrolled 15 participants, in whom diarrhea occurred in 80.0% and vomiting in 53.3%. Safety and effectiveness below 2 years of age have not been established, and the European Union authorization applies from 5 years of age.
- In natural history data, regression began between 12 and 30 months of age in more than 80% of individuals, and the median age of skill loss was 3 years or younger for 46 of 51 developmental skills.

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf); [Percy et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38917793/); [Percy et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40043705/); [EMA Daybu EPAR (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/daybu); [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/); [Neul et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094048/)

<a id="topic-2.2.2.1.9-5"></a>

###### Summary: evidence gaps in supportive care

- Epilepsy: no randomised controlled trials of specific anticonvulsants have been conducted in Rett syndrome, no systematic study has shown one medication or class to be superior, and no definite recommendation is available. Drug-resistant epilepsy affects 20% to 40% of those with seizures, and surgical treatment is generally ineffective. Of those with classic Rett syndrome and a history of epilepsy in one cohort, 74 (12%) were seizure free and off antiseizure medication at last contact. In a cohort of 27 subjects carrying an MECP2 (14) or CDKL5 (13) variant, cannabidiol reduced seizures in 18 of 27 (66.6%) without reaching statistical significance.
- Gastrointestinal and nutrition: 3 (5.9%) neurologists and 4 (8.2%) pediatricians surveyed ranked gastrointestinal management among their five most important treatment goals. Among individuals at risk of suboptimal weight, all-cause mortality was higher after gastrostomy placement (hazard ratio 4.07, 95% CI 1.96 to 8.45), and its long-term impact is described as unclear.
- Scoliosis: scoliosis often does not respond to orthotics. A Rett syndrome diagnosis predicted higher odds of complications (odds ratio 1.98) in admissions for posterior spinal fusion, and the rate of death was lower in those who had scoliosis surgery than in those without surgery (hazard ratio 0.30, 95% CI 0.12 to 0.74).
- Bone health: panel members noted the lack of evidence for the efficacy and safety of bisphosphonates in Rett syndrome, and the bisphosphonate indication statement reached 17/23 (73.9) agreement.
- Anxiety and sleep: no systematic studies of anxiolytics and no anxiety management guidelines exist, and the Natural History Study was not designed to assess their efficacy or safety. Sleep management has no treatment algorithm. In a 4-week double-blind, placebo-controlled crossover trial of melatonin, sleep-onset latency decreased to 19.1 (SE 5.3) minutes during the first 3 weeks, and the long-term effects of chronic use in pediatric patients are unknown.
- Rehabilitation: one publication identified nine physical therapy approaches and reported clinical benefit from them despite an absence of strong research evidence. Across 16 communication intervention studies, intervention was provided to a total of 100 participants. Little evidence specific to Rett syndrome defines whether ongoing, episodic, intensive, or consultative therapy models are optimal at different ages.

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/); [Tarquinio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5278305/); [Krajnc (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4468994/); [Rashid et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12549289/); [Vignoli et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12362169/); [May et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10842289/); [Wong et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29941161/); [Maheshwari (2018)](https://www.ai-online.info/images/ai-ausgabe/2018/04-2018/orphan-supplement-6-2018/2018_4_S117-S124_Rett%20syndrome.pdf); [Stone et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37642479/); [Downs et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26661519/); [Jefferson et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4743907/); [Buchanan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9107202/); [Tascini et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8923297/); [McArthur and Budden (1998)](https://pubmed.ncbi.nlm.nih.gov/9566656/); [Fonzo et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7407501/); [Sigafoos et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37526342/); [Rashid et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396111/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Anticipated population: patients aged 2 years and older

> “The TSHA-102 clinical development program is designed to support the potential future approval for a broad population of patients aged 2 years and older with Rett syndrome through an efficient and rigorously designed pathway.”
> “Taysha designed the TSHA-102 pivotal program so that efficacy data from the REVEAL Pivotal Trial in participants aged 6 to <22 years who have reached developmental plateau can be used to represent patients aged 2 to <6 years, while safety data in younger children are generated through the separate ASPIRE Trial to support a broad label for TSHA-102.”

Source: [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/)

<a id="topic-2.2.2.2-2"></a>

###### Anticipated use: U.S. patient estimate and market research

> “Within the U.S. specifically, patient estimates range from 6,000 to 9,000 based on claims data and epidemiology data. Completed U.S. market research demonstrates strong clinician and caregiver demand and anticipated broad adoption of TSHA-102 across pediatric, adolescent and adult patients with Rett syndrome. The research also indicates a clear preference for intrathecal administration, which is viewed as familiar, accessible and scalable, enabling the potential to safely and efficiently treat patients across institutions.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.2.2.2-3"></a>

###### Care setting: one-time outpatient intrathecal administration

> “Routine outpatient procedure enables scalable access beyond COEs, with ~75% of patients managed outside large Rett COEs”
> “Strong preference for IT delivery over direct-to-brain due to familiarity, accessibility and scalability”
> “Delivered intrathecally as a routine, minimally invasive procedure with outpatient potential, enabling broad, scalable access”

Source: [Taysha Gene Therapies August 2026 corporate presentation (2026)](https://ir.tayshagtx.com/static-files/8da485f7-d48d-42b8-8fa7-388d58d55487)

<a id="topic-2.2.2.2-4"></a>

###### Payer research: value proposition of a one-time outpatient administration

> “TSHA-102 was viewed as a high-value therapy due to its transformative disease-modifying potential in a population with high unmet need, combined with the convenience of a one-time IT administration that can be performed in an outpatient setting”
> “Strong efficacy, safety and durability are expected to drive coverage and reimbursement, with durable functional benefits serving as the key value determinant in this high unmet need setting”

Source: [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm)

<a id="topic-2.2.2.2-5"></a>

###### Route of administration: intrathecal lumbar compared with intracerebroventricular delivery

> “Administration route strongly influences biodistribution: ICV delivery (NGN-401) provides broad brain penetration but requires neurosurgery, whereas intrathecal lumbar injection (TSHA-102) is less invasive but may yield more limited forebrain distribution.”
> “ICV delivery requires neurosurgical placement of a catheter into the lateral ventricle”

Source: [Samanta (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12864443/)

<a id="topic-2.2.2.2-6"></a>

###### Role of neurologists and specialized centers

> “As these therapies progress toward potential regulatory approval, neurologists will play central roles in identifying eligible patients, counseling families, supporting clinical trial enrollment, delivering treatments, monitoring long-term outcomes, and advocating for equitable access.”
> “Access is further constrained by the need for specialized centers capable of administering therapy and monitoring for complications, disproportionately affecting families in rural areas, underserved communities, and low-income countries.”

Source: [Samanta (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12864443/)

<a id="topic-2.2.2.2-7"></a>

###### Current access: clinical trial participation only

> “Access to Taysha’s investigational products is currently available only through participation in a clinical trial for patients who meet the applicable eligibility criteria.”

Source: [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### REVEAL Part A: response across age, disease severity, and genotype

> “Patients were 6‒21 YOA, with diverse clinical histories, broad disease severity (CGI-S 4 to 6), and varied MECP2 mutations to reflect a real-world population”
> “16 DMs in pediatric (n=6) and 15 DMs in adolescent/adult (n=6) patients support the broad treatment potential of TSHA-102”
> “Broad functional impact consistently demonstrated across core disease domains post-TSHA-102 regardless of age, disease severity or genotype”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-2.2.2.3-2"></a>

###### REVEAL Part A: response by dose cohort

> “75% of patients in the high dose cohort achieved ≥2 milestones post-TSHA-102”
> “Average score ≥18 months post-TSHA-102: -15.7 in high dose cohort -7.8 in low dose cohort”
> “TSHA-102 demonstrated early global improvement, with dose-dependent effects that deepened over time in CGI-I”

Source: [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm)

<a id="topic-2.2.2.3-3"></a>

###### Published review: dose response in the first REVEAL cohorts

> “A clear dose–response relationship was observed: participants receiving 1 × 1015 vg demonstrated faster and more pronounced functional gains than those receiving 5.7 × 1014 vg.”

Source: [Samanta (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12864443/)

<a id="topic-2.2.2.3-4"></a>

###### MECP2 variant: genotype coverage of the miniMECP2 transgene

> “By delivering the essential MBD and NID functional domains, TSHA-102 provides a genotype-agnostic approach that encompasses the molecular defects found in over 95% of the RTT population, including the eight most common recurrent mutations and nearly all pathogenic missense variants.”

Source: [Samanta (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12864443/)

<a id="topic-2.2.2.3-5"></a>

###### MECP2 variant and X-chromosome inactivation: sources of variation in disease severity

> “Thus, we have confirmed that MECP2 mutation type is a strong predictor of disease severity. However, clinical severity continues to become progressively worse with advancing age regardless of initial severity.”

Source: [Cuddapah et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4403764/)

> “Because the MECP2 gene is subject to X‐chromosome inactivation (XCI), factors including MECP2 genotypic variation, tissue differences in XCI, and skewing of XCI all likely contribute to the clinical severity of individuals with RTT.”

Source: [Fang et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9034674/)

<a id="topic-2.2.2.3-6"></a>

###### Age at treatment: developmental window

> “Nonetheless, several considerations favor earlier intervention: the first 2–3 years of life represent critical windows of synaptogenesis and circuit formation; prolonged MeCP2 deficiency may lead to structural neuronal and glial changes that become harder to reverse; and treating before or during early regression could prevent milestone loss rather than requiring later recovery (83, 84).”
> “Ultimately, a stratified approach may emerge in which early treatment maximizes developmental potential while older individuals are treated to achieve meaningful functional gains.”

Source: [Samanta (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12864443/)

<a id="topic-2.2.2.3-7"></a>

###### Age at treatment: spontaneous milestone gain before 6 years of age in natural history

> “Before 6 years of age, milestone gain, loss, and regain were more variable and less predictable, with spontaneous first-time gain for a single milestone as high as 97%; inclusion of younger participants without explicit age accounting could increase background spontaneous gain and thereby increase type I error”
> “No consistent significant predictors of gain/regain were identified across the 28 milestones”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-2.2.2.3-8"></a>

###### Children aged 2 to less than 6 years: efficacy extrapolated from older participants

> “A minimum of three months of ASPIRE safety data will be included in the planned BLA submission, while efficacy in the 2 to <6-year-old population will be extrapolated from data collected in the REVEAL pivotal trial.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Consensus guideline: multispecialty care coordinated through a primary care checklist

> “Management of RTT requires input or expertise related to multiple specialties, often necessitating referrals to many providers in addition to the primary care provider.”
> “The checklist (table 1) is suitable for use by health professionals as well as the family as part of their healthcare records, with tables 2–6 providing further detailed guidance.”
> “Review available community and insurance resources (disabled parking permit, respite care and so on).”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.4-2"></a>

###### Consensus guideline: hospitalisation and anaesthesia precautions

> “Individuals may be more sensitive to effects of anaesthetics. They may take longer to awaken from anaesthesia. It is important to ensure anaesthesiologist is aware of current medications (especially anticonvulsants and cannabis preparations), type and description of seizures, breathing abnormalities, and risk of presence of prolonged QTc; a recent ECG is essential.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.4-3"></a>

###### Anaesthesia recommendation: postoperative respiratory care

> “Regardless of the agents used, given the airway and respiratory co-morbid conditions seen in Rett syndrome, postoperative monitoring of respiratory function is recommended.”
> “Non-invasive respiratory support techniques such as BiPAP would facilitate postoperative tracheal extubation in these patients.”

Source: [Maheshwari (2018)](https://www.ai-online.info/images/ai-ausgabe/2018/04-2018/orphan-supplement-6-2018/2018_4_S117-S124_Rett%20syndrome.pdf)

<a id="topic-2.2.2.4-4"></a>

###### Respiratory management: Italian Delphi consensus

> “Noninvasive ventilation should be considered in all RS subjects with sleep respiratory disorders and in those with hypotonia associated with hypercapnia.”
> “Chest physiotherapy should be performed in all RS patients with difficult management of the accumulation of respiratory secretions, using airway clearance techniques and devices (PEP-mask, AMBU bag, or cough machine), more appropriate and tolerated by the patients.”

Source: [Cherchi et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38721909/)

<a id="topic-2.2.2.4-5"></a>

###### Multidisciplinary clinic model: 20 years at a pediatric tertiary hospital

> “The clinic has a diverse team of medical practitioners, including a Pediatrician, Clinical Geneticist and Dentist, along with Allied Health professionals such as a Genetic Counsellor, Dietitian, Physiotherapist, Occupational Therapist, Speech Therapist and a Music Therapist.”
> “The results of this study highlight the usefulness of our clinical model based on multidisciplinary management aimed at preserving and/or prolonging independence in mobility, feeding and communication.”

Source: [Vilvarajan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10454341/)

<a id="topic-2.2.2.4-6"></a>

###### Transition from paediatric to adult care

> “We have a formal programme for transition and transfer of care that takes into account external referrals and ensures continuity of care for those paediatric individuals who are already known to our staff.”
> “The delineation of an adult phenotype in Rett syndrome demonstrates the importance of a transitional programme and the need of a dedicated multidisciplinary team to optimise the clinical management of these patients.”

Source: [Peron et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8685662/)

<a id="topic-2.2.2.4-7"></a>

###### Fragmented care: European caregiver study

> “87% of participants reported having to change their primary physician, with the most common reported reasons including dissatisfaction with care (15%), inadequate follow-up or coordination of care (15%), and evolving needs (17%) (Fig. 5e). Only 3% of RTT patients access a sleep specialist, despite sleep being a highly disruptive issue.”
> “Care was also reported to be geographically fragmented with only 3% of participants reporting that they received all their care at the same location”
> “The changing needs across the lifespan underscore the importance of anticipatory, multidisciplinary care models and improved transition pathways into adulthood.”

Source: [Pulles et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13721293/)

<a id="topic-2.2.2.4-8"></a>

###### Caregiver education for trofinetide gastrointestinal adverse events

> “The nurse coordinators emphasized the importance of participant/caregiver education when introducing a new drug, and their experiences with the GI side effects of trofinetide in the LAVENDER trial informed their communications with the caregivers. A common theme is that, although there are some strategies for managing GI side effects that should be recommended initially (e.g., loperamide for diarrhea), each individual with RTT is unique and different methods may work better in some than others.”

Source: [Moore et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10960750/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

<a id="topic-2.2.2.5-1"></a>

###### FDA post-marketing obligations

No evidence found.

<a id="topic-2.2.2.5-2"></a>

###### Data required by the FDA for inclusion in the planned submission

> “A minimum of three months of ASPIRE safety data will be included in the planned BLA submission, while efficacy in the 2 to <6-year-old population will be extrapolated from data collected in the REVEAL pivotal trial.”
> “The FDA also endorsed our proposed Process Performance Qualification, or PPQ, campaign strategy to support process validation for the BLA submission, including the stability data package, the potency assay strategy, and the execution of BLA-enabling PPQ lots using the commercial manufacturing process.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-2.2.2.5-3"></a>

###### Paediatric investigation plan agreed by the European Medicines Agency

> “A paediatric investigation plan for adeno-associated viral vector serotype 9 containing the human MECP2 gene, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.”
> “A deferral for adeno-associated viral vector serotype 9 containing the human MECP2 gene, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.”
> “Open-label, randomized, 2-part study including a dose-escalation (Part A) and dose expansion (Part B) to evaluate the safety, efficacy, and durability of a single intrathecal dose of TSHA-102 in female children from 2 to less than 9 years of age with Rett syndrome with a documented MECP2 loss-of-function gene mutation.”

Source: [EMA paediatric investigation plan decision (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232894-ema-decision-14-april-2025-agreement-paediatric-investigation-plan-granting-deferral-adeno-associated-viral-vector-serotype-9-containing-human-mecp2-gene_en.pdf-0)

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

<a id="topic-2.2.2.6-1"></a>

###### Post-approval monitoring commitments for TSHA-102

No evidence found.

<a id="topic-2.2.2.6-2"></a>

###### Requirements that would apply after approval

> “Even if we obtain any regulatory approval for TSHA-102, or any future product candidates, such product candidates, once approved, will be subject to ongoing regulatory requirements applicable to manufacturing, labeling, packaging, storage, advertising, promoting, sampling, record-keeping and submitting of safety and other post-market information, among other things.”
> “Any regulatory approvals that we receive for TSHA-102, or any future product candidates may also be subject to a REMS, comparable foreign strategies, limitations on the approved indicated uses for which the drug may be marketed or to the conditions of approval, or requirements that we conduct potentially costly post-marketing testing, including Phase 4 trials and surveillance to monitor the quality, safety and efficacy of the drug.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.2.2.6-3"></a>

###### Continued monitoring of treated participants in the clinical trials

> “These participants will continue to be monitored throughout the study.”

Source: [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/)

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Sponsor-stated goal: one-time treatment of the genetic cause

> “Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-2.2.2.7-2"></a>

###### Pivotal efficacy threshold: developmental milestone response rate

> “A response rate of 33% (5 out of 15 patients) is the minimum threshold for success sufficient to reject the null hypothesis. Based on our natural history data analysis, the null hypothesis is that one out of 15 patients aged ≥ 6 years may gain/regain one of the 28 natural history defined developmental milestone without treatment, corresponding to a response rate of 6.7%.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.2.2.7-3"></a>

###### REVEAL Part A: functional gains over 12 or more months

> “100% of patients (N=12, 6-21 years) in developmental plateau population of gained/regained ≥one DM”
> “At ≥12 months post-TSHA-102, a total of 310 functional gains and improvements were observed (~26 per patient), comprising 31 DMs and 279 additional skill gains/improvements”
> “Durable, multi-domain gains enable independent engagement in daily activities, reduce caregiver burden and enhance social engagement”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-2.2.2.7-4"></a>

###### Caregiver-defined meaningful outcomes of gene therapy

> “According to caregivers, the gain or regain of a developmental milestone would be a meaningful functional improvement post-gene therapy, improving abilities to perform activities of daily living”
> “Incremental improvements were perceived as supporting child autonomy, safety, social interactions, pare burden of care and quality of life”

Source: [Keeley et al. (2025)](https://tayshagtx.com/wp-content/uploads/Every-Gain-Expanding-Possibilities-Caregiver-Insights-on-Meaningful-Improvement-in-Rett-Syndrome-Gene-Therapy-GT.pdf)

<a id="topic-2.2.2.7-5"></a>

###### Payer expectations: durable functional gains

> “Payers emphasized the importance of demonstrating clinically meaningful, durable functional gains and improvements that translate into real-world benefits”

Source: [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm)

<a id="topic-2.2.2.7-6"></a>

###### Uncertainty: durability, long-term safety, and clinically meaningful benefit

> “Determining what constitutes clinically meaningful benefit is equally difficult; families report that even modest gains in independence, communication, or daily living skills are profoundly valuable.”
> “Because gene therapy aims to deliver lifelong MeCP2 expression, long-term safety remains largely unknown. Open questions include durability of expression, feasibility of re-dosing in the context of anti-AAV immunity, potential for delayed toxicity from MeCP2 overexpression, risk of chronic CNS immune responses, and the theoretical possibility of insertional mutagenesis despite low AAV integration rates.”
> “Addressing these uncertainties will require decades-long surveillance; current protocols mandate 15-year follow-up for all treated individuals.”

Source: [Samanta (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12864443/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
